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ABSTRACT 
 
TITLE: SPECIATION OF ACINETOBACTER ISOLATES AND 
DETECTION OF RESISTANCE PATTERN BY PHENOTYPIC AND 
GENOTYPIC METHOD 
 
Introduction: 
 The Genus Acinetobacter are a group of Non-fermentative Gram negative 
bacteria found extensively in natural environment, resulting in colonization and 
infection. Acinetobacter species are the second most common nonfermenter 
isolated from clinical specimens. The infections caused by MDR Acinetobacter 
that are capable of producing various beta lactamases are associated with 
significant morbidity and mortality. Hence Acinetobacter has been added to the 
list of significant microbial challenges of current era. 
 
Aim & Objectives:  
 To determine the prevalent antimicrobial susceptibility pattern and 
various resistance patterns conferred by beta lactamases among the clinical 
isolates of Acinetobacter species, both by phenotypic and genotypic method and 
to correlate the clinical outcome in the patients.  
 
Materials and Methods: 
 About 175 clinically significant, consecutive, non duplicate 
Acinetobacter isolates from various clinical specimens were included in this 
study. The isolates were identified by standard protocols. ESBL production was 
confirmed by CLSI phenotypic confirmatory method, AmpC production was 
confirmed by AmpC disc test and carbapenamase production was detected using 
Modified Hodge test and Imipenem-EDTA combined disc test. Carbapenem 
resistance gene (OXA-23, blaVIM1 & blaIMP1) was identified by PCR. 
 
Results: 
 Acinetobacter baumannii (81.14%) was the most common species 
isolated followed by A.lwoffii (10.29%), A.calcoaceticus (4.57%) and A.junii 
(4%). The maximum isolates were from respiratory samples 63(36.00%) and 
from patients in ICU. There was a significant difference (p value <0.05) 
between the antimicrobial sensitivity pattern of A.baumannii and other species. 
MDR in Acinetobacter spp. was found to be 60%. XDR was found to be 
11.43% and there were no PDR isolate in this study. 20 isolates (11.43%) were 
found to be resistant to meropenem. MIC values were between 32µg/ml and 
256µg/ml. Modified Hodge test was positive in 9 (45%) isolates and IEDT was 
positive in 9(45%) isolates of the 20 meropenem resistant isolates. 61(34.86%) 
isolates were found to be ESBL producers and 23(13.14%) isolates were found 
to be AmpC producers. OXA-23 was positive in all 20 isolates (100%), 
blaVIM1 was positive in 9isolates (45%) and blaIMP1 was positive in 7isolates 
(35%). 
 
Discussion: 
 Acinetobacter species are very notorious for their ability to acquire 
antibiotic resistance because of its potential to respond quickly to the changes in 
selective environmental pressure. A.baumannii was the most common species 
isolated and found to be more resistant when compared to other species. MDR 
Acinetobacter infections were predominant and XDR Acinetobacter infections 
have also been recorded but no PDR Acinetobacter were isolated in this study. 
Extended spectrum beta lactamases and AmpC beta lactamases were also 
detected in a significant number.  Carbapenems remain the drug of choice for 
the MDR acinetobacter infections. But resistance to carbapenems due to 
production of various beta lactamases is of great concern as they are encoded by 
genes which are horizontally transmissible. There is difference between 
phenotypic and genotypic methods in the sensitivity of detection of 
carbapenamases where genotypic methods are more sensitive and remain the 
gold standard. 
 
Conclusion:  
 The high prevalence of Acinetobacter infections emphasizes the need for 
early detection of various beta lactamases, which would help in selection of 
appropriate antibiotic regimen and prevention of emergence and dissemination 
of MDR strains. 
 
Key words:  
 MDR- Multi drug resistant, XDR- Extended drug resistant, PDR- Pan 
drug resistant, ESBL- Extended spectrum beta lactamase, MHT- Modified 
Hodge test, IEDT- Imipenem EDTA combined disc test.  
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INTRODUCTION 
 
 The Genus Acinetobacter are a group of Non-fermentative Gram 
negative bacteria belonging to the family Moraxellaceae. Acinetobacter 
are aerobic, short, stout Gram negative coccobacilli, non-capsulated, non-
motile, non-sporing and oxidase negative.[1]Acinetobacter does not have 
fastidious growth requirements and are able to grow at various 
temperatures and pH. It is found extensively in natural environment. 
Although these organisms are not usually considered as normal human 
flora, the relatively high prevalence of Acinetobacter species in hospitals 
frequently results in colonization and infection in patients.[2] It is usually 
isolated from debilitated patients such as those in ICU, burns patients and 
those who have undergone medical instrumentation or have received 
multiple antimicrobial agents.  
           
 Epidemiology of Genus Acinetobacter is complex. Genotypic 
methods or a combination of genotypic and phenotypic methods are 
required for species identification. Acinetobacter baumannii is the most 
common species isolated from clinical samples and  known to be one of 
the “ESKAPE” pathogen, a group of pathogens with a high rate of 
antibiotic resistance that are responsible for majority of nosocomial 
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infections.  A.lwoffii, A.heamolyticus, A.johnsonii and Genomospecies 3 
and 6 are also isolated from clinical specimens.[1],[3] 
 
 Acinetobacter species are opportunistic pathogens with increasing 
prevalance in nosocomial infections.[3] Levin et al. in 2003 and Poirel et 
al. in 1999 described that 10% of nosocomial infections in ICU patients 
were due to Acinetobacter. Community acquired infections are also 
common in Acinetobacter. It accounts for 10% of all community-acquired 
bacteremic pneumonias.[4] Similarly it is the second most common non-
fermenter isolated from clinical samples.[10] It causes a wide range of 
clinical complications such as pneumonia, septicemia, urinary tract 
infections, skin and soft tissue infections, wound infections and 
meningitis especially in immuno compromised patients.[5]   
          
 Acinetobacter spp have been reported to cause high mortality rate 
of 32% to 52% in blood stream infections. Similarly mortality rates upto 
70% have been reported in ICU acquired pneumonias.[4] Hence the 
identification of Acinetobacter spp. from clinical specimens is very 
essential.       
           
 Different Acinetobacter species have differences in their 
antimicrobial susceptibility pattern, hence it is important to identify 
Acinetobacter isolates at species level.[6]  
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 A.baumannii is the most common species isolated from clinical 
specimens and is particularly formidable because of its propensity to 
acquire antibiotic resistance determinants. They developed 70% 
resistance to third generation cephalosporins, aminoglycosides and 
quinolones and 87% of Acinetobacter isolates were Multidrug 
resistant.[57] 
           
 The genus Acinetobacter have different types of resistance 
mechanisms, which includes antimicrobial inactivating enzymes, reduced 
access to bacterial targets and point mutations that change targets or 
cellular functions.[7] The newer beta lactamases including ESBL, AmpC, 
Non-metallo beta lactamases and Metallo betalactamases are the most 
common emerging causes for antimicrobial resistance.[56] 
          
 In India, it has been reported that 66.7% isolates were ESBL 
producers, 28.57% were AmpC producers, 16.67% were combined ESBL 
and AmpC producers and 47.6% were resistant to carbapenem drugs, in 
which 19% were MBL producers.[12],[56],[59],[60]  For ESBL and AmpC 
producers, carbapenems remain the drug of choice, whereas in 
carbapenem resistant strains we are left with  Tigecycline and polymyxins 
which have started developing resistance to many GNBs.[51] Hence the 
detection of carbapenem resistance is important in the treatment of 
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patients and also preventing the spread of resistant strains, as we have to 
go a long way for newer antibiotics. 
           
 Carbapenem resistance in Acinetobacter may be due to 
oxacillinases, metallobeta lactamases, AmpC beta lactamases or due to 
porin deficiency.[20] Since oxacillinases are chromosomally mediated, 
spread of OXA genes to other organisms is less frequent, when compared 
to MBL, where the spread is plasmid mediated and hence the propensity 
of dissemination is multifold. Also metallo beta lactamases are more 
potent (100-1000 fold) hydrolyzers of carbapenems when compared to 
OXA type carbapenamases which contribute to the carbapenem resistance 
to a greater extent.[59] Hence I focussed my study on identifying the most 
common OXA type carbapenamases OXA-23, MBL genes blaVIM1 and 
blaIMP1 in carbapenem resistant isolates. 
           
 The emergence and the rapid spread of Multidrug resistant isolates 
of Acinetobacter species causing nosocomial infections are of great 
concern worldwide. Because of multidrug resistance of these isolates, it 
poses an intriguing problem to the treating clinician and increasing the 
mortality of the patients. Hence invitro antimicrobial susceptibility 
pattern and identification of resistance pattern is important before treating 
Acinetobacter infections.  
 
5 
 
 Therefore the present study was undertaken to assess the most 
prevalent spp. among Acinetobacter infections, the prevalent antibiotic 
sensitivity pattern, various resistance mechanisms among the isolates and 
the genes involved in carbapenem resistance. This may provide the 
necessary information to formulate a hospital antibiotic policy and also to 
prevent the spread of multidrug resistance strains in the community. 
  
 
 
 
 
 
 
 
Aims and Objectives 
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AIMS AND OBJECTIVES 
 
AIMS: 
            To determine the prevalent antimicrobial susceptibility pattern 
and various resistance patterns conferred by beta lactamases among the 
clinical isolates of Acinetobacter species and to correlate the clinical 
outcome in the patients.  
 
OBJECTIVES:  
1. To identify and speciate the clinically significant Acinetobacter 
isolates from various clinical specimens. 
2.  To identify the prevalent antimicrobial susceptibility pattern of 
these isolates. 
3. To determine the Meropenem MIC for the meropenem resistant 
isolates by Macrobroth dilution method as per CLSI guidelines. 
4. To identify the Carbapenem resistance conferred by beta 
lactamases (Non-Metallobeta lactamases, Metallo betalactamases 
and AmpC beta lactamases) in meropenem resistant isolates. 
5. To detect Extended spectrum beta lactamases (ESBL) and AmpC 
beta lactamases in Acinetobacter isolates by phenotypic methods. 
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6. To identify the carbapenem resistance by genotypic method- by 
identifying  Oxacillinase gene OXA-23 and Metallo betalactamases 
genes bla-IMP1 and bla- VIM1 in meropenem resistant isolates by 
PCR. 
7. To analyze the clinical outcome of the patients in the study group. 
                          
  
  
 
 
 
 
Review of Literature 
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REVIEW OF LITERATURE 
 
 The Genus Acinetobacter are a group of Taxonomically diverse, 
non fermentative Gram negative rods.[4] They all share the common 
phenotypic features like failing to acidify the butt of  Klingler iron 
medium or Triple sugar iron medium or of oxidative fermentative media 
and grow only under aerobic conditions using oxygen as the final electron 
acceptor in the respiratory pathway.[10],[46] 
 
3.1 TAXONOMY:  
3.1.1 HISTORY: 
 The Genus Acinetobacter has colourful taxonomic history. They 
were identified in the first decade of 20th century.[4] Acinetobacter was 
frequently misidentified due to lack of differentiating features.  
 
 Genus Acinetobacter are a group of Gram negative bacteria 
belonging to Gammaproteobacteria.[11] It was first described in 1908 as 
Diplococcus mucosus. The lack of distinctive characteristics was a 
driving force in the evolving nomenclature: Micrococcus (small), Mima 
(mimics), Achromobacter (colourless), Acinetobacter (motionless), and 
anitratus (nitrate not reducing).  
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 The first strain of Acinetobacter spp were isolated by M.W. 
Beijerinck, a Dutch Microbiologist in 1911 from soil and were named as 
Micrococcus calcoaceticus.[8] In the year 1930s and 1940s, De Bord 
proposed a new tribe, Mimaeae, to encompass these organisms. Later 
Brisou and Prevot in 1954 proposed the genus Acinetobacter to include 
colourless, nonmotile, saprophytic gram-negative bacilli regardless of the 
oxidase activity. 
           
 In the year 1971, the Subcommittee on the Taxonomy of 
Moraxella and Allied Bacteria proposed that the genus Acinetobacter 
should include only the oxidase negative strains.[8] In the year 1984, 
Bergey’s Manual of Systematic Bacteriology classified Acinetobacter in 
the family Neisseriaceae, but more recently the molecular taxonomic 
studies have resulted in the reclassification of this organism in the new 
family Moraxellaceae in 1991.[11] This family also includes Moraxella, 
Psychrobacter and related organisms. The genus Acinetobacter belongs 
to,  
 
 Phylum   - Proteobacteria 
          Class       - Gammaproteobacteria 
          Order        - Pseudomonadales 
          Family      - Moraxellaceae 
          Genus       - Acinetobacter 
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3.1.2 CLASSIFICATION:  
 The genus characteristics of Acinetobacter was made clear by 
1971. They are gram negative rods or coccobacilli, catalase positive, 
oxidase negative, non- motile, non-sporing and may be capsulated. 
Phenotypic identification is possible using a scheme proposed by Bouvet 
and Grimont.[27] The presumptive identification is possible with the above 
mentioned characteristics. 
  
  Differentiation of Acinetobacter spp. is difficult with the means 
typically available in most clinical microbiology laboratories. The first 
species identified was A.calcoaceticus. Initially the scientists had 
distinguished the species based on the ability to produce acid from 
glucose or not. By this A.calcoaceticus was distinguished into two 
variants, A.calcoaceticus var.anitratus which produce acid from glucose 
and A.calcoaceticaus var.lwoffii which do not produce acid.[4] 
 
 Other methods of species identification includes bacteriocin typing, 
phage typing, characterization of outer membrane proteins, serotyping, 
phenotyping, ribotyping, transfer ribonucleic acid (tRNA), genomic 
fingerprinting and DNA homology studies.[8]  
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 The Epidemiological identification of a strain was done using  
pulsed field gel electrophoresis, amplified fragment length 
polymorphism(AFLP), randomly amplified polymorphic DNA-
polymerase chain reaction(RAPD-PCR), MLST, electrospray ionization 
mass spectrometry (PCR/ESI-MS) or ribotyping.[9] Fluorescent Lactose 
Denitrification (FLN) was used to identify the different species of 
bacteria in this genus  by  the amount of acid produced due to metabolism 
of glucose.[46] 
 
 In 1986, based on the DNA-DNA hybridization studies Bouvet & 
Grimont identified 12 genomic species. In 1989 it is increased to 17, now 
33 different genomic species have been identified, of which 17 have been 
named and others will carry the genomic species number.[13]  
 
Acinetobacter Nomenclature: 
 Acinetobacter calcoaceticus (genomic species 1),  A.baumannii 
(genomic species 2), A.haemolyticus (genomic species 4), A.junii 
(genomic species 5), A.johnsonii (genomic species 7), A.lwoffii (genomic 
species 8/9), A.radioresistens (genomic species 12), A.baylyi, A.bouvetii, 
A.gerneri, A.grimontii, A.parvus, A.schindleri, A.tandoii, A.tjernbergiae, 
A.towneri, A.ursingii, A.venetianus and Acinetobacter species unnamed. 
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 Genomospecies 1,2,3 and 13 of Tjernberg and Ursing may be 
difficult to distinguish in the clinical laboratory and have been referred to 
as Acinetobacter calcoaceticus-baumannii complex.[8] A.johnsonii, 
A.lwoffii and A.radioresistens are the natural inhabitants of human skin, 
commensal in oropharynx and vagina. A.schindleri are commonly 
isolated from vagina, cervix, throat, nose, ear, conjunctiva and urine, it is 
mostly regarded as clinically insignificant.[23] 
 
 A.baylyi, A.bouvetii, A.grimontii, A.tandoii, A.tjernbergiae and 
A.towneri were not commonly isolated from human specimens. 
 
3.1.3 MORPHOLOGY: 
 Members of the genus Acinetobacter are gram negative rods or 
coccobacilli. During the exponential phase they appear bacillary to 
coccobacillary forms but become more coccoid or diplococcal in the 
stationary phase and in non selective agars.[8] Individual cells are 1 to 1.5 
by 1.5 to 2.5µm in size sometimes difficult to decolourise with a 
tendency to retain the crystal violet.[10] Hence clinical Microbiologist 
must be aware that Acinetobacter species may appear as gram positive in 
initial cultures. 
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3.1.4 CULTURAL CHARACTERISTICS: 
 Members of the genus Acinetobacter are strictly aerobic, catalase 
positive, oxidase negative gram negative rods growing at a wide range of 
temperatures and pH, optimally at 37˚C. They may be capsulated in older 
cultures, non-motile occasionally an odd twitching motility can be 
demonstrated and non- sporing.[8] They do not reduce nitrates to nitrites, 
this distinguishes these organisms from Enterobacteriaceae.[4] They are 
not fastidious and most strains grow in defined media containing single 
carbon and energy source which accounts for its prevalence in nature.[9] 
 
 The colonies are 1-2mm in diameter which are smaller than 
Enterobacteriaceae, dome shaped, smooth, slightly mucoid and opaque 
with grayish white or yellowish pigmentation. Acinetobacter are 
nonlactose fermenters but it may produce a pinkish hue on MacConkey 
agar.[8] Hemolytic property on Blood agar is variable.     
 
 Some special media like Leeds Acinetobacter Medium and Liquid 
Enrichment medium have been used for the isolation of Acinetobacter 
species from various clinical specimens and from environmental 
samples.[13] 
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3.1.5 BIOCHEMICAL CHARACTERISTICS: 
Organism Genomospecies 
Growth 
at 37˚C 
Growth 
at 44˚C 
Haemo 
lysis 
OF 
glucose 
Arginine 
hydrolysis 
Malonate 
utilization 
A.calcoaceticus 1 + - - + + + 
A.baumannii 2 + + - + + + 
A.haemolyticus 4 + - + V + - 
A.lwoffii 8/9 + - - - - - 
A.junii 5 + - - - + - 
A.johnsonii 7 + - - - V V 
 
           
            The Genus Acinetobacter does not form Indole, does not acidify 
the butt of TSI, citrate is not utilized, urease is not produced and nitrate is 
not reduced to nitrites.[1] Main differentiation between the species is 
based on the saccharolytic property. It acidifies most OF carbohydrates, 
in particular definitive identification is made by demonstrating the rapid 
production of acid from 1% or 10% lactose. 
 
3.1.6 AUTOMATED METHODS FOR IDENTIFICATION: 
 Vitek 2 and Phoenix are the two methods which are available for 
detection of Acinetobacter from specimens, but their detection rate to 
identify the organism at species level is poor. Hence it is not used 
routinely.   
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3.2 EPIDEMIOLOGY: 
 Acinetobacter species are ubiquitous in the environment.[8] 
Acinetobacter species may be isolated from a common source such as 
computer key boards, Bp cuffs, parenteral nutrition or dust in the interior 
of mechanical ventilator or from the dialysis machine.[9] 
 
 They are normally isolated from moist areas like axilla, groin and 
toe webs. They are commensals in the respiratory tract (7%) and exhibit 
25% of cutaneous colonization in healthy adults.[4] A.lwoffii (58- 61%) is 
the most common skin colonizer followed by A.johnsonii (20%), 
genomospecies 15 (12%), A.junii (10%), A.radioresistens (8%), 
genomospecies 3 (5%) and A.baumannii (0.5-3%). Generally it colonizes 
the human skin 44% in non-hospitalized and  75% in hospitalized 
patients.[9] A.baumannii colonization is very low in normal individuals but 
it has higher end during hospitalization. In 1986 Larson et al. in his study 
found that acinetobacters were the most common gram negative 
organism found on the hospital personnel.[8]  
 
3.2.1 BURDEN OF DISEASE: 
 WORLDWIDE: 
 The multidrug resistant Acinetobacter spp especially Acinetobacter 
calcoaceticus baumannii complex isolation were showing a rising trend 
all over the world. The first carbapenamase enzyme in a resistance strain 
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was found in Scotland in 1985.[16] Till 2002 carbapenem resistance was 
not a major health problem in Europe. From 2003 the isolation of 
resistant strains has been increased. 
           
          The National Infection Surveillance System showed Imipenem 
resistance has been increased from 0% to 20%. In USA Imipenem 
resistance was reported as 39.8%.[101] Similarly army personnel returning 
from Afghanistan Iraq conflict showed Imipenm resistance of 37%.[100] 
Imipenem resistance in Australia is started from 1999.[16] 
           
 Carbapenem resistance seems to be highest in the countries of 
Turkey, Greece, Italy, and England and the rates appear to be the least in 
countries of Germany and The Netherlands. Pneumonia due to 
Acinetobacter in critically ill patients is more in Asia (4-44%) and 
European (0-35%) hospitals than in US hospitals (6-11%). The 
Acinetobacter isolates from Asian and European countries were resistant 
to aminoglycosides and Piperazillin Tazobactum in higher proportion 
when compared to United States. This data suggests the growing threat of 
Acinetobacter infection in critically ill patients especially in Asia and 
Europe.[21]   
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3.2.2 INDIA: 
 In India, it has been reported that 66.7% isolates were ESBL 
producers, 28.57% were AmpC producers, 16.67% were combined ESBL 
and AmpC producers and 47.6% were resistant to carbapenem drugs, in 
which 19% were MBL producers.[12],[56],[59],[60] 
 
 Carbepenem resistance is reported from various parts of India. A 
study conducted by Sinha et al. in 2011 in North India showed 87% of 
isolates were MDR and 20% were resistant to Meropenem.[5] Similarly a 
study conducted in the same year showed 14.8% of A.baumannii isolates 
were Meropenem resistant and 86% were MDR.[18] 
 
 An incidence of 14.2% Acinetobacter strains resistant to 
carbapenem was documented in a study from Christian Medical College, 
Vellore.[17] Similarly a study from All India Institute of Medical Sciences, 
New Delhi in 2005 has given a prevalence of 34.7% resistance to 
meropenem , from St. John’s Medical College, Bangalore  resistance rate 
of 14% and from  Chandigarh in 2003 resistance rate of 20% have been 
documented.[19],[20]    
           Gaynes et al. have documented 17% of XDR and Jyoti Sharma et 
al. have documented 22.38% of PDR Acinetobacter spp. in India.[95],[96] 
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3.3PATHOGENESIS:        
3.3.1 VIRULENCE FACTORS: 
 Lipopolysaccharide – Because of lipopolysaccharide, 
Acinetobacter O antigen display a marked hydrophobocity with the 
ability to grow on hydrophobic substrates. 
 
 Capsule – The presence of polysaccharide capsule protects against 
phagocytosis.  
 Fimbriae – Fimbriae facilitate the adhesion to human epithelial 
cells. 
 Protein S layers and Slime also potentially enhance the virulence 
of the organism. 
 Certain strains of Acinetobacter have been shown to produce 
siderophores and iron-repressible outer membrane receptor 
proteins.  
 Enzymes – Enzymes such as butyrate esterase, caprylate esterase 
and leucine arylamidase potentially involved in damaging tissue 
lipids. 
 Bacteriocin production may enhance the survival of Acinetobacter. 
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 Biofilm – Biofilm formation is a well known pathogenic 
mechanism in device associated infections. The excess 
polysaccharide formation in A.baumannii leads to difficulty in 
antibiotic penetration and also the differences in cell physiology in 
biofilm increases the drug resistance.[22]  
 
3.3.2 CLINICAL MANIFESTATIONS: 
           The major drawback in the identification of Acinetobacter 
infection is the interpretation in the significance of isolates from clinical 
samples.[4]  
 
RESPIRATORY TRACT: 
 This is the most common site of infection due to pharyngeal 
colonization. Community acquired bronchiolitis and tracheobronchitis 
have been reported in healthy children.[4] Similarly 10% of community 
acquired pneumonia in adults is due to Acinetobacter and it accounts for 
20% of gram negative pneumonia.[15]  The major impact is the ventilator 
associated pneumonia in ICU patients due to nosocomial spread. It is also 
associated with high mortality rate of 40% to 60%.[9] Corbella et al. 
indicate that colonization of digestive tract is an epidemiological 
reservoir in the development of  ventilator associated pneumonia.[14] 
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BACTEREMIA: 
 The bacteremia due to Acinetobacter will occur late during 
hospitalization. It is mainly followed by respiratory tract infections and 
through the indwelling catheters. A.baumannii was the tenth most 
common cause for monomicrobial blood stream infection and the 
mortality rate was 17% to 46%, followed by A.lwoffii, A. junii and 
A.parvus.[9] 
 
URINARY TRACT: 
 Acinetobacter though colonizes the lower urinary tract, it is rarely 
invasive. Indwelling bladder catheter or nephrolithiasis may cause cystitis 
and pyelonephritis due to Acinetobacter.[4] 
 
SOFT TISSUE INFECTION: 
           The major pathogen in traumatic wounds, postoperative incisions 
and burns is Acinetobacter because of its ability to thrive in the 
devitalized tissues. 
 
MISCELLANEOUS INFECTIONS: 
 Acinetobacter spp may also be reported from various clinical 
syndromes like intra cranial infections, soft tissue infections, 
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conjunctivitis, endophthalmitis, endocarditis, arthritis, osteomyelitis, 
pancreatitis and liver abscess.[100],[102] 
 
3.3.3 RISK FACTORS: 
 Acinetobacters are generally non pathogenic but it may cause 
infections in debilitated individuals. It is the second most nonfermenter 
isolated from the human specimens next to P.aeruginosa.[10]  
 
 Risk factors for community acquired infection include alcoholism, 
cigarette smoking, chronic lung disease and diabetes mellitus.[15] For 
nosocomial infections length of hospital stay is the important cause 
followed by surgery, wounds, previous infection, fecal colonization, 
indwelling catheters, admission to ICU or burns unit, parenteral nutrition, 
mechanical ventilation and breaches in infection control protocols. 
 
3.4 ANTIMICROBIAL SUSCEPTIBILITY PATTERN: 
 Different species of Acinetobacter exhibit differences in 
antimicrobial susceptibility pattern.[6] Hence species identification and its 
specific susceptibility pattern is very essential. Initially Acinetobacter 
infections were treated with beta lactam antibiotics like third generation 
cephalosporins, extended spectrum penicillins, penicillins-beta lactam 
inhibitor combinations and fluoroquinolones.[49] Nowadays due to the 
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development of various resistance mechanisms, the antibiotic treatment 
regimen for Acinetobacter infection is very much narrowed.[103] 
 
3.5 MECHANISM OF RESISTANCE: 
          During 1970s, the Acinetobacter isolates were susceptible to the 
major group of antibiotics. From 1975, most of the isolates were resistant 
to first and second generation cephalosporins retaining susceptibility to 
third and fourth generation caphalosporins, aminoglycosides, 
fluoroquinolones and carbapenems. At that time all the isolates were 
100% susceptible to Imipenem.[18]  
 
          The Worldwide emergence and spread of Imipinem resistant 
Acinetobacter strains started appearing in the late 1980s and 1990s.[26] 
Till that time Carbapenem remained the only drug to treat severe 
Acinetobacter infections. Due to the emergence of Carbapenem resistant 
strains, the Polymyxins and Tigecycline came to use, which also 
developed resistance in recent years.[18],[37],[39],[40] The extent of 
antimicrobial resistance in Acinetobacter spp. can be explained with 
varied definitions. 
 
 Multi Drug Resistant (MDR) – The isolate resistant to at least three 
classes of antimicrobial agents including all penicillins, 
cephalosporins, fluoroquinolones and aminoglycosides. 
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 Extensive Drug Resistant (XDR) - The isolate will be resistant to 
carbapenems in addition to the above mentioned drugs. 
 
 
 Pan Drug Resistant (PDR) – The isolate will be resistant to all the 
available drugs, including polymyxins and tigecycline. 
 
 The mechanism of resistance in Acinetobacter involves the 
following three broad categories [7]: 
 
(1) Antimicrobial inactivating enzymes. 
(2) Reduced access to bacterial targets. 
(3) Point mutations that change targets or cellular functions. 
 
 These mechanisms may combine to act in the same 
microorganisms as in other gram negative bacteria. 
 
3.5.1 Resistance to Betalactam Antibiotics: 
 A wide array of beta-lactamases are present in Acinetobacter.[42] 
The beta-lactamases causes hydrolysis of beta lactam ring and confer 
resistance to penicillins, caphalosporins and carbapenems.[27] The 
resistance to betalactam antibiotics is not only mediated by beta-
lactamases enzymes but also by the efflux pumps. 
 
The beta-lactamases are classified by two systems: 
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Ambler’s classification – It is a molecular classification based on amino 
acid sequences. 
 
Bush-Jacoby Medeiros classification – It is a functional classification.   
 Ambler’s Classification: 
Class A  - Penicillinase (eg.TEM, SHV) 
Class B  -   Metallo betalactamase (eg.IMP, VIM) 
Class C  -   Cephalosporinase –AmpC (eg.CMY,NMC) 
Class D  -  Oxacillinase (eg.OXA 23, OXA 58) 
Class A, C and D require serine moieties for their function, similarly 
Class B require zinc for its action. 
 
 Bush-Jacoby Medeiros classification[65],[66] 
Group Enzyme Molecular class 
Inhibited by 
Clavulanic acid
1 Cephalosporinase C No 
2a Penicillinase A Yes 
2b Broad spectrum A Yes 
2be Extended spectrum A Yes 
2br Inhibitor resistant A Diminished 
2c Carbenicillinase A Yes 
2d Cloxacillinase D or A Yes 
2e Cephalosporinase A Yes 
2f Carbapenamase A Yes 
3 Carbapenamase B No 
4 Penicillinase  No 
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The beta-lactamases may be chromosomal or plasmid mediated. 
 
Carbapenamases: 
 The first serine carbapenamase in A.baumannii was isolated from 
blood culture in 1985, in Scotland.[16] This was followed by its occurrence 
in Spain, France, Japan, Singapore, Cuba, Brazil, China and Kuwait. 
Class D (OXA) carbapenamases are the main cause for carbapenem 
resistance. A.baumannii inherently exhibit OXA-51 hence it is used for 
the confirmation of A.baumannii isolates. Expression of these enzymes 
also require insertion sequence element ISAba 1. 
 
 Generally carbapenamases are classified based on sequence 
homology into: OXA-23 (includes OXA-27 and OXA-49), OXA-24 
(includes OXA 25, 26 and 40) and OXA 58. OXA-23 was the first 
iaolated carbapenamase enzyme and most common carbapenamase gene 
in Acinetobacter. It is both chromosomal and plasmid mediated. OXA-24 
is both chromosomal and plasmid mediated, less frequent than OXA-23, 
restricted to United States and Europe. OXA-58 is recently isolated from 
France.[30],[31] 
 
 Acinetobacter also express Ambler class B Metallo-beta-
lactamases (MBLs) like IMP, VIM and SIM-1.[43] MBL genes are mobile 
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genetic elements that can be transferred easily which pose a great threat 
of spread.[25] These genes have been isolated from various parts of the 
world. The first MBL gene was isolated in Pseudomonas aeruginosa in 
1991. In India, MBL production among A. baumannii isolates has been 
reported as 42%. Anuradha et al. from Bombay reported 33.33% of MBL 
in 2008.[50]The most prevalent MBL gene was blaIMP-1.[23] Another 
study from south India states that blaVIM was the most common gene in 
Metallobeta-lactamase producing  A.baumannii isolates.[24],[41]MBL is 
also expressed by  A.junii. 
 
 The carbapenem resistance is also mediated by AmpC 
betalactamases when present along with decreased membrane 
permeability or due to alterations in penicillin binding proteins. [32],[47] 
 
AmpC Betalactamases: 
 AmpC type cephalosporinase are inherently expressed by 
A.baumannii known as Acinetobacter derived cephalosporinases (ADC). 
These will hydrolyse aminopenicillins and extended spectrum 
cephalosporins. Inducible type of AmpC is not expressed by 
Acinetobacter. Its expression is mediated by the presence of upstream 
insertion sequence known as ISAba 1 and ISA 1135.[28],[29] 
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Extended-spectrum Betalactamases (ESBLs): 
 Ambler class A beta-lactamases are reported in Acinetobacter 
species. The first ESBL reported in A.baumannii was PER-1which was 
confined to Turkey initially, but now it has spread throughout the World. 
It is either chromosomal or plasmid mediated requires insertion sequence 
ISPa 12 for its expression. The other ESBLs reported in A.baumannii are 
PER-2, VEB-1, TEM-1, TEM-2 and carbenicillinase CARB-5. CTX-M-2 
and CTX-M-43 also been reported. [33],[34] 
 
Co-production of ESBL and AmpC Betalactamases: 
 The genus Acinetobacter has high level expression of the natural 
production of AmpC type beta lactamases. The AmpC producing 
organism can act as a hidden reservoir for the ESBLs. The high level 
expression of AmpC β-lactamases may mask the recognition of the 
ESBLs and it may result in fatal and inappropriate antimicrobial 
therapy.[56] Hence the detection of ESBL among the AmpC producers 
helps in the appropriate treatment of the patients. The coproduction of 
ESBL and AmpC in A.baumannii was reported as 16.67%.[56]   
 
3.5.2 Resitance to Quinolones: 
  Flouroquinolone resistance is mediated by DNA topoisomerase, 
acquisition of mobile genetic elements or through efflux pumps. The 
mutation in topoisomerase enzyme like gyrA and parC leads to the 
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modifications of lipopolysacharides which also confers resistance in 
A.baumannii.[36],[49] 
 
3.5.3 Resistance to Aminoglycosides: 
 Plasmid or transposons coded Aminoglycoside-Modofying 
Enzymes (AMEs) or efflux pumps are involved in aminoglycoside 
resistance.[35] 
 
3.5.4 Resitance to Tigecycline: 
 The overexpression of AdeABC multidrug efflux pump confers 
resistance to Tigecycline and also to many other antibiotics like 
tetracycline, aminoglycosides and quinolones.[25],[38],[51] 
 
3.5.5 Resitance to Colistin: 
 The modification in the lipopolysaccharides of the bacterial cell 
membrane due to point mutation interfere with the binding of the 
antimicrobial agents like Colistin.[37],[51] 
 
3.6 LABORATORY METHODS TO DETECT RESISTANCE 
MECHANISMS: 
3.6.1 Phenotypic Methods: 
Screening Methods: 
Carbapenamase Detection: 
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          Carbapenamases are capable of hydrolyzing carbapenems, other 
betalactams and betalactamase inhibitors with the exception of 
Aztreonam. With reference to CLSI 2014 document, disc diffusion 
testing using discs with 10μg potency of Imipenem and Meropenem is 
used as a screening test for carbapenamase production. The isolates 
having zone diameter of ≤22mm and ≤14mm with Imipenem & 
Meropenem respectively are categorized as resistant.[48] 
 
AmpC Betalactamase Detection: 
 AmpC betalactamases are resistant to beta lactamase inhibitors, all 
betalactams including Cephamycins except Carbapenems. Isolates 
showing resistance to Cefoxitin (zone size < 18mm) should be considered 
as probable AmpC producers.[60],[63],[64] 
 
Extended spectrum Betalactamase Detection: 
 ESBLs are capable of hydrolyzing penicillins – 
oxyiminocephalosporins and Monobactams (Aztreonam) and are 
inhibited by betalactamase inhibitors but have no detectable activity 
against Cephamycins or Carbapenems. Isolates exhibiting resistance to 
one or more third generation cephalosporins like cefotaxime (30µg/ml), 
ceftrioxone (30µg/ml) and ceftazidime (30µg/ml) with reference to CLSI 
2014 AST interpretive criteria are considered to be ESBL producers.[48] 
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Confirmatory Methods: 
Carbapenamase Detection 
 Imipenem-EDTA combined disc test[53] 
 Imipenem EDTA double disc synergy test[56]  
 EDTA disc potentiation test[54] 
 Modified Hodge test[54] 
 MBL E test[53] 
AmpC Betalactamases  
 Modified three dimensional test[56] 
 AmpC disc test[54] 
 Detection by cefoxitin agar media[60] 
 Detection by inhibitor based method[60] 
 AmpC betalactamase E test[60] 
Extended spectrum β lactamase  
 CLSI phenotypic confirmatory method[48] 
 Double disc diffusion synergy test[56] 
 Three dimensional test 
 Modified Three dimensional test 
 Inhibitor potentiated disc diffusion test[56] 
 ESBL E strip method 
 Automated methods. 
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3.6.2 Molecular Methods: 
            Polymerase Chain Reaction (PCR) is a technique which 
amplifies a specific DNA target region, so as to obtain a million or more 
copies which can then be easily visualized by using DNA staining 
techniques for the identification of resistance conferring genes. PCR is 
the gold standard procedure to determine the resistant genes, since the 
phenotypic methods have not yet been standardized for NFGNBs but cost 
prohibiting.          
 
3.7 THERAPEUTIC OPTIONS: 
 The therapeutic options for the management of MDR, XDR and 
PDR of Acinetobacter spp. infections have declined due to emergence 
and dissemination of antimicrobial resistance even to many last line 
drugs. 
 
3.7.1 Treatment of MDR Acinetobacter species: 
 Carbapenem remains the drug of choice for the treatment of MDR 
Acinetobacter spp. MYSTIC surveillance program documented that 
Imipenem is more potent than Meropenem for MDR, because efflux 
pumps affect Meropenem to a greater degree when compared to 
Imipenem. Hence both Imipenem and Meropenem susceptibility should 
be done.[25]  
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3.7.2 Treatment of XDR and PDR Acinetobacter species: 
 The treatment of XDR Acinetobacter spp.infections include 
Polymyxins and Tigecycline as the last resort. [38] 
 
Tigecycline:   
 This drug is a glycycline agent which received approval from the 
Food and Drug Administration in June 2005.[61],[62] It is a broad-spectrum, 
parenteral and bacteriostatic agent. Its acts by blocking the protein 
synthesis. There is no interpretive criteria for tigecycline as per CLSI 
guidelines.[48]  The guidelines laid down by FDA was used in many 
studies.[61] The major side effects are nausea, vomiting and diarrhea. 
Tigecycline can be used as combination therapy.[103] High degree of 
resistance to tigecycline has also been reported in Acinetobacters.[51] 
 
Polymyxins: 
 Because of limited therapeutic options, polymyxins like polymyxin 
B and polymyxin E (colistin) came into use.[39],[40] Colistimethate is 
produced by Bacillus colistinus. It is hydrolyzed to colistin. It has 
bactericidal activity and its effect is concentration dependant. Colistin is a 
cationic detergent which acts by increasing the cell permeability by 
altering the lipopolysaccharide component in the bacterial cell membrane 
leading to cell death. Its use is limited because of its major adverse effects 
like nephrotoxicity, neurotoxicity and pulmonary toxicity. Many studies 
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have proved that colistin is effective in the treatment of MDR 
Acinetobacter spp. and other MDR organisms.[44] 
 
Betalactamase Inhibitors: 
 Acinetobacter strains are intrinsically susceptible to Sulbactam, a 
betalactamase inhibitor. The combination therapy involving beta lactam 
antibiotic with its inhibitor combination does not have any significant role 
when comparing to betalactamase alone.[45] 
 
Combination Therapy: 
          The combination therapy including sulbactam, rifampicin, 
aminoglycosides, carbapenems and colistin can be tried for treating XDR 
and PDR Acinetobacter spp.[40],[44],[46] 
 
3.8 FACTORS AFFECTING OUTCOME OF THE PATIENT: 
 The presence of chronic and acute co-morbid conditions influences 
the patient outcome. The chronic conditions include diabetes, 
hypertension and immunosuppressive states and the acute conditions 
include dyselectrolytemia, cardiovascular compromise etc.  
 
3.9 CONTROL MEASURES: 
 The persistence of MDR Acinetobacter spp. in health care settings 
could be due to several factors including the presence of susceptible 
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patients, the patients with colonization or infection, selective pressure 
from antimicrobial use and poor infection control procedures. Hence 
stringent measures should be taken to control and prevent the spread of 
MDR Acinetobacter infections.[25] 
 
Infection control practices:[25] 
1. Standard precautions, environmental cleaning and disinfection. 
2. Point source control effective during the outbreak. 
3. Contact barrier precaution to health care personnel. 
4. Cohorting of patients. 
5. Cohorting of healthcare personnel. 
6. Clinical unit closure during outbreak to interrupt transmission and 
for thorough environmental disinfection. 
7. Judicious use of antimicrobials to prevent drug resistance by 
antimicrobial stewardship. 
8. Passive and active surveillance to identify colonized or infected 
patients, so that interventions can be implemented. 
  
  
 
 
 
 
Materials and Methods 
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MATERIALS AND METHODS 
 
Place of study: 
           This cross sectional study was conducted in the Institute of 
Microbiology, Madras Medical College, Rajiv Gandhi Government 
General Hospital, Chennai. 
 
Study period: 
          The study period was for one year from September 2013 to August 
2014. 
 
Ethical consideration: 
          Approval was obtained from the Institutional ethics committee 
before the commencement of the study. Informed consent was obtained 
from all the patients participated in this study. All patients satisfying the 
inclusion criteria were included. Patients were interviewed by structured 
questionnaire. 
 
Statistical analysis: 
          Statistical analyses were carried out using Statistical Package for 
Social Sciences (SPSS). The proportional data of this cross sectional 
study were tested using Pearson’s Chi Square analysis test &Fisher Exact 
test. 
36 
 
Study Population: 
           A total of 175 clinically significant, consecutive, non duplicate 
isolates of Acinetobacter spp. were enrolled in this study. The isolates 
were from various clinical specimens sent to the Microbiology 
department for bacteriological culture, biochemical identification and 
antibiotic susceptibility testing. Isolates included in this study were 
obtained from blood, sputum, endotracheal aspirate, bronchial wash, 
pleural fluid, ascitic fluid, peritoneal dialysis fluid, cerebrospinal fluid, 
urine and wound swabs. 
 
Inclusion criteria: 
1. Clinically significant, consecutive, non duplicate isolates were 
included in the study. The significance of the isolate was based on 
two or more of the following criteria - clinical history, presence of 
organism in Gram stain, presence of intracellular forms of the 
organism and pure growth in culture with a significant colony 
count wherever applicable. 
2. Patients aged more than 18 years.  
 
Exclusion criteria: 
1. Isolates of repeated samples from the same patient were not 
included in the study. 
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2. Patients with colonization of Acinetobacter with no apparent 
clinical illness. 
3. Patients aged less than 18 years were not included. 
 
 Preliminary identification of isolates belonging to Genus 
Acinetobacter was done based on the following characteristics, 
 
4.1 COLONY MORPHOLOGY: 
 On Nutrient agar - Translucent colonies 1-2 mm in diameter with 
smooth surface, slightly mucoid and opaque with grayish white 
pigmentation and some strains with yellow pigmentation. 
 
 On Blood agar - circular colonies with or without haemolysis. 
 
 On MacConkey agar - Lactose non fermenting colonies but 
sometimes with pinkish hue. 
 
 On CLED - circular, 1-1.5mm in diameter lactose non fermenting 
colonies.  
 
 The isolates obtained were subjected to preliminary tests like Gram 
staining, Catalase test, Oxidase test and Motility by Hanging drop 
method.(APPENDIX - II ) 
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 The isolates which were Gram negative bacilli or Gram negative 
coccobacilli, catalase positive, oxidase negative and non-motile by 
hanging drop were subjected to biochemical reactions for further 
confirmation. 
 
 The following preliminary biochemical reactions were done with 
appropriate controls - Mannitol motility medium for mannitol 
fermentation, Triple sugar iron agar medium for sugar fermentation 
and hydrogen sulphide production, Indole production using 
Kovac’s reagent and Citrate utilization on Simmons Citrate 
Medium. 
 
 Isolates giving the following reactions were further processed in 
the study:- 
 
 Mannitol motility medium- mannitol not fermented, non motile. 
 
 Triple sugar iron agar- Alkaline slant/alkaline butt, no gas or 
hydrogen sulphide production. 
 
 Indole was not formed on adding Kovac’s reagent to 24hr broth 
culture. 
 
 Absence of growth and absence of change in colour from apple 
green to blue denotes non utilization of citrate. 
39 
 
 
4.2 SPECIATION OF ACINETOBACTER ISOLATES: 
Phenotypic characterization: 
          The isolates which were identified as belonging to the Genus 
Acinetobacter were subjected to the following biochemical reactions for 
speciation. 
 
 Hugh Leifsons OF medium: A set of semisolid medium 
containing 1% glucose was inoculated with a young agar slope 
culture. One of the tube was immediately overlaid with sterile 
paraffin oil to produce anaerobic condition. The species which 
utilizes carbohydrates produces an acid reaction in the open tube 
only.  
 
 Arginine dehydrolase test: Isolated colonies were stab inoculated 
into Moller decarboxylase medium with Arginine and overlaid 
with a 5mm layer of sterile paraffin oil, incubated at 37ºC for 24 
hrs. Violet discolouration of the medium denotes positive reaction, 
and a yellow discolouration as negative reaction. 
 
 Malonate utilization test: Malonate broth was inoculated with a 
young agar slope culture and incubated at 37˚C for 48hours. The 
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change in colour from green to blue indicates positive reaction, no 
colour change indicates negative reaction. 
 
 Nitrate reduction test: Nitrate reduction broth was inoculated 
with a young agar slope culture and incubated at 37˚C for 96hours. 
After incubation 0.1ml of a mixture containing alpha napthylamine 
and sulfanilic acid in equal proportion was added. The 
development of red color within a few minutes indicates the 
presence of nitrite and the ability of the organism to reduce nitrate. 
The absence of red color indicates the inability of the organism to 
reduce nitrate.     
 
 Heamolytic property: The culture from a young agar slope was 
inocualted onto 5% sheep blood agar for the identification of 
heamolysis, as A.haemolyticus produces haemolytic colonies and 
other species are non-haemolytic. 
 
 Growth at variable temperature: The culture from a young agar 
slope was inocualted onto two Nutrient agar plates and was 
incubated at 37˚C and at 42˚C respectively. The presence/absence 
of growth at two different temperatures was used in the species 
identification. 
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BIOCHEMICAL CHARACTERISTICS: 
Organism Growth at 37˚C 
Growth 
at 44˚C Haemolysis
OF 
glucose 
Arginine 
hydrolysis 
Malonate 
utilization
A.calcoaceticus + - - + + + 
A.baumannii + + - + + + 
A.haemolyticus + - + V + - 
A.lwoffii + - - - - - 
A.junii + - - - + - 
A.johnsonii + - - - V V 
 
4.3 ANTIMICROBIAL SENSITIVITY TESTING: 
4.3.1 Disc diffusion method: 
            Antibiotic sensitivity was performed for all the isolates by Kirby -
Bauer disc diffusion method using cation adjusted Mueller-Hinton agar 
plate. Three to four colonies were suspended in nutrient broth and were 
incubated for two hours at 37ºC, so as to get the organism in the 
logarithmic phase. The density of the suspension was standardized with 
nutrient broth, visually equivalent to 0.5 McFarland units. Within fifteen 
minutes of preparation of the suspension, a sterile cotton-wool swab was 
dipped into the suspension and the surplus was removed by rotating the 
swab against the side of the test tube. With this swab, the agar plate was 
inoculated by even streaking of the swab over the entire surface of the 
plate in three directions so as to obtain a lawn culture. After brief drying, 
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the antibiotic disc was placed, 5 on each plate. All the batches of 
antibiotics were quality checked as per standard guidelines. The control 
strains were included as per the CLSI guidelines. 
The panel of drugs used for antimicrobial sensitivity testing was as 
follows; 
ANIBIOTICS 
 
RESISTANT 
(mm) 
INTERMEDIATE 
(mm) 
SENSITIVE 
(mm) 
Cefotaxime (30µg) ≤ 14 15-22 ≥ 23 
Ceftazidime (30µg) ≤ 14 15-17 ≥ 18 
Cefepime (30µg) ≤ 14 15-17 ≥ 18 
Amikacin (30µg) ≤ 14 15-16 ≥ 17 
Gentamycin (10µg) ≤ 12 13-14 ≥ 15 
Ciprofloxacin(5µg) ≤ 15 16-20 ≥ 21 
Piperazillin / 
Tazobactum 100/10µg) ≤ 17 18-20 ≥ 21 
Trimethoprim 
/Sulfamethoxazole 
(1.25/23.75µg) 
≤ 10 11-15 ≥ 16 
Imipenem (10µg) ≤ 18 19-21 ≥ 22 
Meropenem (10µg) ≤ 14 15-17 ≥ 18 
Tigecycline (15µg) ≤12 13-15 ≥16 
Polymyxin B (300U) ≤10 - ≥14 
Colistin (10µg) ≤11 - ≥14 
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 Interpretations were made using the Clinical and Laboratory 
Standards Institute, USA guidelines (January 2014, M100-S24- 
Volume 34 No.1, Table 2B-2, Page 62/63). 
 
 Journal reference was used for Polymyxin B and Colistin Disc 
diffusion standards as no CLSI guidelines exist for the same.[57],[58] 
 
 For Tigecycline the guidelines laid down by F.D.A. were 
used.[61],[62] 
 
4.3.2 Minimum inhibitory concentration (MIC) for detecting 
Meropenem Resistance Using Macrobroth Dilution Method: 
           MIC was determined for the isolates which were showing 
resistance to Meropenem (< 18mm) by disc diffusion method. 
 
1. Culture media: cation adjusted Mueller Hinton broth (pH 7.2-7.4). 
 
2. Preparation of antibiotic stock solution: 
 Meropenem used for preparing stock solution was obtained from 
Macleods.  
 
 Antibiotic stock solution was prepared using the formula,                   
1000 
        W =    -------------------    x V x C 
P 
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    Where P= potency of the antibiotic in relation to the base. (For   
Meropenem, P= 675/1000 mg) 
               V = volume of the stock solution to be prepared (10ml) 
                 C = final concentration of the antibiotic solution (1024μg/ml) 
                 W = weight of the antibiotic to be dissolved in the volume V 
 
 15.17 mg of drug was mixed with 10ml of distilled water which 
contains 1024µg/ml concentration of drug.  
 
3. Preparation of antibiotic dilutions: 
- Two rows each of 14 sterile test tubes were arranged in the rack 
(1 row for the test & 2nd row for ATCC control). 
- Using micropipette 1ml of MH broth was transferred to all the 
tubes in the rack. 
- From the stock solution 1 ml was transferred to the first tube in 
each row and mixed well. 
- From the first tube 1 ml of the antibiotic solution was transferred 
to second tube.  
- This procedure was repeated till the 14th tube. 
- One tube containing only antibiotic solution was kept as control. 
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4. Inoculum preparation for the test and ATCC control: 
- 9.9 ml of MH broth was taken in a sterile test tube. 
- 0.1ml of 0.5 McFarland turbidity matched test organism was 
added to broth and mixed well. 
- From the above inoculum 1 ml was transferred to each tube 
containing antibiotic dilutions. 
- One tube containing only test inoculum was kept as control 
- Same procedure was repeated for ATCC control strain. 
 
5. Incubation: 
           The test tubes were incubated at 37ºC overnight. 
 
 Interpretation: 
- MIC of ATCC control strain and the test organism was observed. 
- The lowest concentration of the antibiotic which shows clearing 
was considered as the MIC for the ATCC strain & for the test 
isolate.   
 
MIC of Meropenem[48]: 
 ≤ 2μg/ml  - Susceptible 
    4μg/ml  - Intermediate 
  ≥8μg/ml  - Resistant  
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4.4 DETECTION OF ANTIMICROBIAL RESISTANCE 
MECHANISMS: 
Phenotypic Method: 
 All the isolates which were included in this study were subjected to 
Carbapenemase screening test using Meropenem disc, AmpC screening 
test by Disc antagonism test using Cefoxitin disc and ESBL screening test 
using Cefotaxime and Ceftazidime discs. The screen test positive isolates 
were subjected to respective confirmatory tests using appropriate 
antibiotic discs that were quality checked.  
 
4.4.1 Carbapenamase detection:     
 The isolates which were resistant to Meropenem by disc diffusion 
method as per CLSI guidelines was used as the indicator for 
carbapenamase production and tested for Oxacillinase, Metallo 
betalactamase and AmpC betalactamase production.[69],[70] 
 
 4.4.1A Oxacillinase detection by Modified Hodge Test: 
 Lee et al. has described the MHT for detection of 
Carbapenamase.[52] A 0.5 McFarland standard suspension of  E.coli 
ATCC 25922 from an overnight culture was prepared and was diluted 
1:10 in saline or broth. The MHA plate was inoculated with the 
suspension as for disc diffusion procedure and allowed to dry for 5 to 10 
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minutes. The 10µg of Ertapenem disc (Himedia) was placed in the centre. 
The test isolate was then streaked from the edge of the disc to the 
periphery of the plate along with positive and negative controls and 
incubated at 37˚C for 24 hours. The length of the streak should be 20 to 
25mm.[53],[54] 
 
Interpretation: 
 Enhanced growth of the test strain towards the zone of inhibition - 
positive for carbapenamase production. 
 
 No enhanced growth of the test strain towards the zone of 
inhibition - negative for carbapenamase production. 
 
Quality control Organisms: 
 Positive control    - K.pneumoniae ATCC BAA-1705 
 Negative control  - K.pneumoniae ATCC BAA-1706 
 
4.4.1B Metallo Beta lactamase Detection by Imipenem(IMP)-EDTA 
Combined Disc Test: 
 The test isolate was inoculated onto MHA plates as for disc 
diffusion procedure.  Two Imipenem discs (10µg) (Himedia) were placed 
on the MHA plate. 10µl of EDTA solution (750µg) was added to one of 
the Imipenem disc. The plate was incubated at 37˚C for 24hrs. The 
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increase in zone size of ≥7mm around Imipenem EDTA as compared to 
Imipenem was interpreted as a positive result.[52],[53],[93] 
 
4.4.1C AmpC Betalactamase Detection by AmpC Disc Test: 
 A lawn culture of ATCC E.coli 25922 was prepared on a MHA 
plate. A disc containing 10µg of Cefoxitin (Himedia) was placed on the 
surface of agar.  Sterile disc was moistened with 20µl sterile saline and 
inoculated with several colonies of the test organism. The inoculated disc 
was then placed beside the Cefoxitin disc almost touching on the 
inoculated plate. The plates were incubated overnight at 37˚C. A positive 
test appears as flattening or indentation of the cefoxitin inhibition zone in 
the vicinity of the test disc.[54],[63],[64]  
 
4.4.2 AmpC Betalactamase Detection by AmpC Disc Test: 
 The isolates with zone size of less than 18mm for cefoxitin disc 
was considered as screening test positive for AmpC. They were further 
confirmed with AmpC disc test as described above. 
 
4.4.3 ESBL Detection by CLSI Phenotypic Confirmatory Method: 
 In this method a lawn culture of test isolate was made as for disc 
diffusion procedure.[48] Ceftazidime clavulanic acid disc(30µg/10µg) 
(Himedia) and ceftazidime disc 30µg (Himedia) were  placed on the 
surface of the plate. The test isolate was considered to produce ESBL, if 
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the zone size around the β lactamase inhibitor combination disc was 
increased by ≥5mm. The test was performed with appropriate controls. 
 
4.5 MOLECULAR METHOD:    
Polymerase chain reaction:      
 The isolates which were resistant to Meropenem by Kirby Bauer 
Disc diffusion method irrespective of phenotypic methods were subjected 
to conventional PCR for the detection of Oxacillinase gene OXA-23 and 
Metallo Beta Lactamases genes bla-IMP1 and bla-VIM1.[72],[73]  
 
DNA extraction: 
 5-10 Acinetobacter colonies were inoculated into nutrient broth and 
incubated overnight at 37ºC. 1.5ml of overnight broth culture was 
transferred into 2.5ml of centrifuge tube and centrifuged at 10,000 rpm 
for 3 minutes. Supernatant was discarded, excess medium was removed 
by gently tapping the tube on a paper towel. 
 
Procedure: 
1. The pellet obtained was suspended in 200µl of PBS. 
2. 180µl of Lysozyme digestion buffer and 20µl of Lysozyme were 
added. 
3. Above mixture was mixed well and incubated at 37 ºC for 15min. 
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4. After incubation 200µl of Lysis buffer and 20µl of Proteinase K 
[10mg/ml] were added and incubated at 56ºC for 10min in 
waterbath. 
5.  Then 300µl of Isopropanol was added and mixed well. 
6. The whole lysate was transferred into PureFast spin column and 
centrifuged at 10000rpm for 1min. 
7. Flow through was discarded and 500µl of Wash buffer-1 was 
added to spin column and centrifuged at 10000rpm for 1min. 
8. Flow through was discarded and 500µl of Wash buffer-2 was 
added to spin column and centrifuged at 10000rpm for 1min. 
washing was repeated one more time. 
9. Flow through was discarded and the spin column was centrifuged 
for additional 2 minutes to remove any residual ethanol. 
10. The DNA was eluted by adding 100µl of Elution buffer and 
centrifuged for 1min. The eluted DNA was used as the template for 
PCR. 
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Primers: [Designed by HELINI Biomolecules, Chennai] 
 
GENE PRIMER SEQUENCES AMPLICON SIZE 
OXA-23  
(F) 
 
(R) 
 
5'-CTTGCTCGTGCTTCGACCGAGT-3’  
 
160bp 
 5'-CGCCTAGGGTCATGTCCTTTTC-3' 
VIM1       
(F) 
 
(R) 
 
5'-GTGCTTTGACAACGTTCGCT-3'  
422bp 
 5'-TCCACGCACTTTCATGACGA-3 
IMP1       
(F) 
 
(R) 
 
5'-TTTTGCAGCATTGCTACCGC-3' 
 
220bp 
5'-CACGCTCCACAAACCAAGTG-3 
 
PCR Procedure: 
1. Reactions were set up as follows; 
Components Quantity 
HELINI 2X PCR Master Mix 10μl 
Primer Mix 10pmoles/Reactions 5μl 
Genomic DNA 5μl 
Total volume 20μl 
 
2. All the components were mixed gently and placed into Corbett 
Reseach thermocycler and programmed it as follows, 
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Cycle 
Number Denaturation Annealing Extension 
1 94ºC for 5 min - - 
35 94ºC for 30sec 58ºC for 30sec 72ºC for 30sec 
1 - - 72º C for 5 min 
 
Agarose gel electrophoresis: 
1. 2% agarose gel was prepared [2gm of agarose in 100ml of 1x TAE 
buffer] with eight wells. 
2. 8μl 6X Gel loading dye was mixed to each PCR vial. 
3. 15μl from each PCR vial was loaded. 
4. Then 100bp DNA ladder and appropriate controls were loaded. 
5. Electrophoresis was run at 50V for 45 min and the bands were 
observed using UV Transilluminator. 
 
Interpretation: 
 The amplified PCR products and 100bp DNA molecular markers 
were seen as bright fluorescent bands with satisfactory controls. A 160bp 
corresponds to OXA-23, 422bp corresponds to blaVIM1 and 220bp 
corresponds to blaIMP1 gene. 
  
  
 
 
 
Results 
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RESULTS 
 
 This cross sectional study was conducted in the Institute of 
Microbiology, Madras Medical College in association with various other 
Departments at the Rajiv Gandhi Government General Hospital, Chennai 
during the period of Sep 2013 to Aug 2014. A total of 175 clinically 
significant, consecutive, non duplicate isolates of Acinetobacter species 
from various clinical specimens were included in the study. All the 
isolates were identified by standard procedures. 
 
TABLE 1: GENDER DISTRIBUTION OF PATIENTS (n= 175) 
SEX NO. OF PATIENTS PERCENTAGE% 
MALE 120 68.57% 
FEMALE 55 31.43% 
 
 There was a male predominance (68.57%) among the isolates 
obtained from the patients. 
FIGURE-1: GENDER DISTRIBUTION OF PATIENTS (n =175) 
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TABLE 2: AGE DISTRIBUTION OF PATIENTS (n=175) 
AGE IN YEARS 
NO. OF PATIENTS 
PERCENTAGE % 
MALE FEMALE TOTAL 
18-20 7 3 10 5.71% 
21-40 28 20 48 27.43% 
41-60 59 25 84 48.00% 
>60 26 7 33 18.86% 
 
 The maximum number of isolates were from the patients in the age 
group of 41 – 60 years (48.0%) followed by 21 – 40 years (27.43%). 
 
FIGURE-2: AGE AND GENDER DISTRIBUTION OF PATIENTS 
(n =175) 
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TABLE 3: DISTRIBUTION OF ACINETOBACTER ISOLATES FROM 
VARIOUS CLINICAL SPECIMENS (n =175) 
 
SAMPLES TOTAL NUMBER PERCENTAGE % 
Urine 45 25.71% 
Endotracheal aspirate 41 23.43% 
Wound swab 41 23.43% 
Blood 17 9.71% 
Sputum 12 6.86% 
Bronchial wash 7 4.0% 
PD fluid 5 2.86% 
CSF 3 1.71% 
Pleural fluid 2 1.14% 
Ascitic fluid 2 1.14% 
 
FIGURE-3: DISTRIBUTION OF ACINETOBACTER ISOLATES FROM 
VARIOUS CLINICAL SPECIMENS (n =175) 
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TABLE4: DISTRIBUTION OF ACINETOBACTER ISOLATES IN VARIOUS        
CLINICAL SPECIMENS FROM DIFFERENT WARDS (n = 175) 
 
SPECIALITY SPECIMEN NUMBER TOTAL PERCENTAGE% 
ICU 
ET aspirate 26 
36 20.57% 
Blood 4 
Urine 4 
Sputum 1 
Wound swab 1 
MEDICAL 
WARD 
Urine 19 
31 17.71% 
Blood 6 
Sputum 2 
Ascitic fluid 2 
Pleural fluid 2 
NEURO 
SURGERY 
ET aspirate 15 
26 14.86% 
CSF 3 
Urine 3 
Wound swab 5 
SURGICAL 
WARD 
 
Wound swab 20 
24 13.71% 
Urine 4 
NEPHROLOGY 
 
 
 
 
Urine 9 
21 12% 
Blood 5 
PD fluid 5 
Sputum 2 
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SPECIALITY SPECIMEN NUMBER TOTAL PERCENTAGE% 
ORTHO 
PAEDICS 
WARD 
Wound swab 13 
15 8.57% 
Urine 2 
THORACIC 
MEDICINE 
Sputum 7 
14 8% Bronchial 
wash 7 
 
OTHERS 
 
 8 8 4.57% 
 
 Most of the isolates were from the Intensive care unit (20.57%), 
followed by Medicine unit (17.71%), Neuro surgery (14.86%) and 
Nephrology (12%). 
 
FIGURE 4: DISTRIBUTION OF ACINETOBACTER ISOLATES IN VARIOUS        
CLINICAL SPECIMENS FROM DIFFERENT WARDS (n =175) 
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TABLE 5: SPECIES OF ACINETOBACTER ISOLATED (n =175) 
 
 
S.NO.  SPECIES ISOLATED NO. OF ISOLATES PERCENTAGE % 
1 A.baumannii 142 81.14% 
2 A.lwoffii 18 10.29% 
3 A.calcoaceticus 8 4.57% 
4 A.junii 7 4% 
 
 
 Acinetobacter baumannii (81.14%) was the most common species 
isolated followed by A.lwoffii (10.29%), A.calcoaceticus (4.57%) and 
A.junii (4%). 
 
FIGURE-5: DISTRIBUTION OF ACINETOBACTER SPECIES 
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TABLE 6: DISTRIBUTION OF ACINETOBACTER SPECIES IN VARIOUS        
CLINICAL INFECTIONS (n =175) 
 
INFECTIONS A.baumannii A.lwoffii A.calcoaceticus A.junii 
Respiratory 
tract infections 61 - 1 - 
Wound  
infections 27 7 3 4 
Urinary tract 
infections 34 6 2 1 
Septicemia 9 3 - 2 
Cirrhosis 2 1 1 - 
CKD 6 1 1 - 
Hydrocephalus 3 - - - 
 
  
           A.baumannii was isolated from respiratory tract infections 
followed by wound infections, urinary tract infections and septicemia. 
A.lwoffii was isolated from wound infections and UTI. A.calcoaceticus 
was isolated from wound infections. A.junii was isolated from wound 
infections and septicemia.  
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TABLE 7: DISTRIBUTION OF ACINETOBACTER SPECIES IN VARIOUS        
CLINICAL SPECIMENS (n =175) 
 
SPECIES SPECIMEN NUMBER TOTAL PERCENTAGE%
A.baumannii 
ET aspirate 41 
142 81.14% 
Urine 34 
Wound swab 27 
Sputum 11 
Blood 10 
Bronchial 
wash 7 
PD fluid 5 
CSF 3 
Pleural fluid 2 
Ascitic fluid 2 
A.lwoffii 
Wound swab 7 
18 10.29% Urine 6 
Blood 5 
A.calcoaceticus 
Urine 4 
8 4.57% Wound swab 3 
Sputum 1 
A.junii 
Wound swab 4 
7 4% Blood 2 
Urine 1 
 
 A.baumannii was isolated from ET aspirate, urine, wound swab, 
blood, sputum, bronchial wash and body fluids.  A.lwoffii, 
A.calcoaceticus and A.junii were isolated from wound swab, blood and 
urine. 
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 TABLE 8: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF A.baumannii 
Drugs 
Total Number 
( n = 142 ) Percentage % 
Sensitive Resistant Sensitive Resistant 
Cefotaxime 19 123 13.38 86.62 
Ceftazidime 29 113 20.42 79.58 
Cefepime 47 95 33.09 66.91 
Amikacin 61 81 42.96 57.04 
Gentamycin 38 104 26.76 73.24 
Ciprofloxacin 27 115 19.01 80.09 
Pip - Taz 88 54 61.97 38.02 
Cotrimoxazole 27 115 19.01 80.09 
Imipenem 125 17 88.03 11.97 
Meropenem 122 20 85.92 14.08 
Tigecycline 118 24 83.10 16.90 
Polymyxin- B 137 5 96.48 3.52 
Colistin 142 - 100 - 
 
 
FIGURE 6: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF 
A.baumannii 
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TABLE 9: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF A.lwoffii 
 
Drugs 
Total Number 
( n = 18 ) Percentage % 
Sensitive Resistant Sensitive Resistant 
Cefotaxime 6 12 33.33 66.67 
Ceftazidime 10 8 55.56 44.44 
Cefepime 13 5 72.22 27.78 
Amikacin 11 7 61.11 38.89 
Gentamycin 8 10 44.44 55.56 
Ciprofloxacin 5 13 27.78 72.22 
Pip - Taz 15 3 83.33 16.67 
Cotrimoxazole 3 15 16.67 83.33 
Imipenem 18 - 100 - 
Meropenem 18 - 100 - 
Tigecycline 17 1 94.44 5.55 
Polymyxin- B 18 - 100 - 
Colistin 18 - 100 - 
 
FIGURE 7: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF A.lwoffii 
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TABLE 10: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF 
A.calcoaceticus 
 
Drugs 
Total Number 
( n = 8 ) 
Percentage % 
 
Sensitive Resistant Sensitive Resistant 
Cefotaxime 6 2 75 25 
Ceftazidime 8 - 100 - 
Cefepime 8 - 100 - 
Amikacin 7 1 87.50 12.50 
Gentamycin 6 2 75 25 
Ciprofloxacin 3 5 37.50 62.50 
Pip - Taz 8 - 100 - 
Cotrimoxazole 3 5 37.50 62.50 
Imipenem 8 - 100 - 
Meropenem 8 - 100 - 
Tigecycline 7 1 87.50 12.50 
Polymyxin- B 8 - 100 - 
Colistin 8 - 100 - 
  
FIGURE 8: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF 
A.calcoaceticus 
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TABLE 11: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF A.junii 
 
 
FIGURE 9: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF A.junii 
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Drugs 
Total Number 
( n = 7 ) Percentage % 
Sensitive Resistant Sensitive Resistant 
Cefotaxime 4 3 57.14 42.86 
Ceftazidime 5 2 71.43 28.57 
Cefepime 5 2 71.43 28.57 
Amikacin 3 4 42.86 57.14 
Gentamycin 1 6 14.29 85.71 
Ciprofloxacin 1 6 14.29 85.71 
Pip - Taz 6 1 85.71 14.29 
Cotrimoxazole 1 6 14.29 85.71 
Imipenem 7 - 100 - 
Meropenem 7 - 100 - 
Tigecycline 6 1 85.71 14.29 
Polymyxin- B 7 - 100 - 
Colistin 7 - 100 - 
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TABLE 12: COMPARISON OF ANTIMICROBIAL SENSITIVITY PATTERN 
AMONG ACINETOBACTER SPECIES (n =175) 
 
 
DRUGS 
 
A.BAUMANNII
(n =142) 
OTHER 
SPP. 
(n=33) TEST 
P 
VALUE 
SIGNIFI 
CANCE 
SEN RES SEN RES
Cefotaxime 19 123 16 17 Chi-square 0.001 Significant 
Ceftazidime 29 113 23 10 Chi-square 
 
0.001 
 
Significant 
Cefepime 47 95 26 7 Chi-square 
 
0.001 
 
Significant 
Amikacin 61 81 21 12 Chi-square 
 
0.032 
 
Significant 
Gentamycin 38 104 15 18 Chi-square 
 
0.035 
 
Significant 
Ciprofloxacin 27 115 9 24 Chi-square 
 
0.290 
 
Significant 
PT 88 54 29 4 Chi-square 
 
0.004 
 
Significant 
Cotrimoxazole 27 115 7 26 Chi-square 
 
0.774 
 
Non-
Significant 
Imipenem 125 17 33 0 Fisher’s Exact 
 
0.045 
 
Significant 
Meropenem 122 20 33 0 Fisher’s Exact 
 
0.016 
 
Significant 
Polymyxin-B 137 5 33 0 Fisher’s Exact 
 
0.585 
 
Non-
Significant 
Tigecycline 118 24 30 3 Chi-square 
 
0.004 
 
Significant 
 
 There was a significant difference between the antimicrobial 
sensitivity pattern of A.baumannii and other species since p value is  
<0.05 for cephalosporins, aminoglycosides, quinolones and carbapenems. 
But there was no significant difference for cotrimoxazole and  
polymyxin-B. 
  
66 
 
TABLE 13: DETECTION OF MEROPENEM RESISTANCE IN 
ACINETOBACTER ISOLATES BY DISC DIFFUSION METHOD (n=175) 
 
PATTERN OF 
RESISTANCE NO OF ISOLATES PERCENTAGE % 
Susceptible 155 88.57% 
Resistant 20 11.43% 
 
 175 isolates of Acinetobacter species were screened for 
meropenem resistance by Kirby -Bauer disc diffusion method, of which 
20 isolates (11.43%) were found to be resistant to meropenem.  
 
FIGURE 10: DISTRIBUTION OF MEROPENEM RESISTANCE IN 
ACINETOBACTER ISOLATES  
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TABLE 14: PROFILE OF MEROPENEM RESISTANT ISOLATES (n =20) 
 
ISOL
ATE 
NO. 
AGE/ 
SEX 
CLINICAL 
DIAGNOSIS 
WARD SPECIMEN 
RISK 
FACTORS 
SPECIES 
ISOLATED 
1 45/F Urosepsis SUR urine Indwelling catheter A.baumannii 
2 47/M Poisoning ICU urine Indwelling catheter A.baumannii 
3 43/M RTA/Head injury NS Blood 
Mechanical 
ventilation A.baumannii 
4 45/M BB Fracture (left) Ortho urine 
Indwelling 
catheter A.baumannii 
5 50/M Post TB ICU ET aspirate Immuno compromised A.baumannii 
6 34/M Post Renal transplant Nephro urine 
Immuno 
compromised A.baumannii 
7 48/M Post Renal transplant Nephro urine 
Immuno 
compromised A.baumannii 
8 35/M Above knee amputation Ortho 
Wound 
swab 
Multiple 
antibiotics A.baumannii 
9 58/M Septicemia ICU Blood Mechanical ventilation A.baumannii 
10 60/F Poisoning ICU ET aspirate Mechanical ventilation A.baumannii 
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ISOL
ATE 
NO. 
AGE/ 
SEX 
CLINICAL 
DIAGNOSIS 
WARD SPECIMEN 
RISK 
FACTORS 
SPECIES 
ISOLATED 
11 62/F MCTD ICU ET aspirate Immuno compromised A.baumannii 
12 58/F Pneumonia ICU ET aspirate Immuno compromised A.baumannii 
13 45/M Pneumonia MED Sputum Immuno compromised A.baumannii 
14 58/M Aspiration pneumonitis ICU ET aspirate 
Immuno 
compromised A.baumannii 
15 40/F Poisoning ICU ET aspirate Mechanical ventilation A.baumannii 
16 28/M RTA/Head injury NS ET aspirate 
Mechanical 
ventilation A.baumannii 
17 47/M RTA/Head injury/SDH NS 
Wound 
swab 
Mechanical 
ventilation A.baumannii 
18 20/M RTA/Head injury NS 
Wound 
swab 
Mechanical 
ventilation A.baumannii 
19 20/M CSOM ENT Wound swab 
Multiple 
antibiotics A.baumannii 
20 20/F Post Renal transplant Nephro Urine 
Immuno 
compromised A.baumannii 
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TABLE 15: MIC FOR MEROPENEM RESISTANT ISOLATES  
(n =20) 
 
 The 20 isolates which were resistant to Meropenem by disc 
diffusion method were further tested for their meropenem minimum 
inhibitory concentration.  
 
MIC for 
Meropenem 
(μg/ml) 
512 256 128 64 32 16 8 4 2 1 0.5 0.25 
A.baumannii 
(n=20) - 9 5 5 1 - - - - - - - 
P.aeruginosa 
ATCC 27853 
(control) 
         1   
 
 All the 20 isolates have their MIC values greater than 8µg/ml, 
hence they are resistant to meropenem. Among the 20 isolates, 9(45%) 
isolates have256µg/ml as MIC, 5(25%) isolates have 128 µg/ml as MIC, 
another 5(25%) isolates have 64 µg/ml as MIC and remaining 1(5%) 
isolate has 32 µg/ml as MIC. 
 
FIGURE 11: DISTRIBUTION OF MEROPENEM MIC VALUES 
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TABLE 16: PHENOTYPIC DETECTION OF RESISTANT MECHANISMS 
FOR MEROPENEM (n=20) 
 
 The meropenem resistance by Kirby -Bauer disc diffusion method 
was taken as the indicator for carbapenamase production and was further 
tested for their mechanisms of carbapenam resistance conferred by beta 
lactamases by phenotypic methods. 
 
PHENOTYPIC 
TESTS METHOD 
NO. OF       
ISOLATES 
PERCENTAGE 
% 
POSITIVE 
 
 
Modified Hodge Test 
(MHT) 9 45% 
Imipenem-EDTA 
combined disc test  
(IEDT) 
9 45% 
AmpC Disc Test 6 30% 
MHT, IEDT & AmpC 
Disc Test 3 15% 
MHT & IEDT 7 35% 
NEGATIVE MHT, IEDT and Ampc Disc Test 7 35% 
 
 
 Among the 20 isolates, Modified Hodge test was positive in 9 
(45%) isolates, IEDT was positive in 9(45%) isolates, AmpC Disc test 
was positive in 6(30%) isolates and 7(35%) isolates were negative for all 
the three phenotypic methods. Out of the 20 isolates, 3(15%) isolates 
were positive for MHT, IEDT and AmpC disc test and 7(35%) isolates 
were positive for MHT and IEDT. 
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TABLE 17: MOLECULAR DETECTION OF RESISTANT MECHANISMS 
FOR MEROPENEM (n=20) 
 
 The Meropenem resistant isolates were tested for most common 
carbapenamase gene OXA – 23 and metallo betalactamase genes blaVIM1 
and blaIMP1 by PCR  
 
GENES TESTED POSITIVE ISOLATES PERCENTAGE% 
OXA – 23 20 100% 
blaVIM1 9 45% 
blaIMP1 7 35% 
     
 Among the 20 meropenem resistant isolates, all the 20 isolates 
were positive for OXA-23 (100%), 9 (45%) isolates were positive for 
blaVIM1 and 7 (35%) isolates were positive for blaIMP1. 
 
FIGURE 12: DISTRIBUTION OF VARIOUS GENES AMONG THE 
MEROPENEM RESISTANT ISOLATES 
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TABLE 18: COMPARISON OF PHENOTYPIC AND GENOTYPIC 
METHODS IN MEROPENEM RESISTANT ISOLATES 
 
PHENOTYPIC 
TEST 
RESULTS 
GENES TESTED 
OXA – 23 blaVIM1 blaIMP1 
Positive Negative Positive Negative Positive Negative
Positive 
MHT (n = 9) 9 - 2 7 5 4 
Positive 
IEDT (n = 9) 9 - 3 6 6 3 
Positive 
AmpC Disc Test 
(n=6) 
6 - 2 
 
4 
 
3 3 
MHT, IEDT & 
AmpC Disc test 
Positive (n =3) 
3 - 2 1 3 - 
Phenotypic tests 
Negative (n =7) 7 - 3 4 1 6 
 
 
 Among the 9MHT positive isolates, all the 9 isolates were OXA-23 
positive, 2 were blaVIM1 positive and 5 were blaIMP1 positive. Similarly 
among the 9 IEDT positive isolates all the 9 were OXA-23 positive, 3 
were blaVIM1 positive and 6 were blaIMP1 positive. Among the 6 AmpC 
disc test positive isolates, all of them were OXA-23 positive, 2 were 
blaVIM1 positive and 3 were blaIMP1 positive. Similarly in the 7 
phenotypic negative isolates, all were OXA-23 positive, 3 were blaVIM1 
positive and 1 isolate was blaIMP1 positive.  All the three genes were 
positive in 2 (10%) isolates, similarly both blaVIM1 and blaIMP1 were 
positive in 2 (10%) isolates.  
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TABLE 19: DETECTION OF EXTENDED SPECTRUM BETA LACTAMASE 
IN ACINETOBACTER ISOLATES (n=175) 
 
 
ESBL PRODUCTION NO OF ISOLATES PERCENTAGE % 
Positive 61 34.86% 
Negative 114 65.14% 
 
 175 isolates of Acinetobacter species were screened for ESBL 
production and confirmed by CLSI phenotypic confirmatory method. 
61(34.86%) isolates were found to be ESBL producers. 
 
TABLE 20: DISTRIBUTION OF ESBL AMONG ACINETOBACTER SPP. 
 (n = 175) 
 
SPECIES SPECIMEN NUMBER TOTAL PERCENTAGE%
A.baumannii 
Wound swab 15 
 
 
 
 
 
56 
 
 
 
 
 
32.00% 
ET aspirate 14 
Urine 10 
Sputum 8 
Br wash 4 
Body fluids 4 
Blood 1 
A.lwoffii 
Wound swab 3 
4 2.29% 
Blood 1 
A.junii Blood  
1 
 1 0.57% 
 
 The Extended spectrum beta lactamases were common in 
A.baumannii (32.00%), followed by A.lwoffii (2.29%) and A.junii 
(0.57%). 
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FIGURE 13: DISTRIBUTION OF ESBL IN ACINETOBACTER ISOLATES 
 
 
 
 
 
TABLE 21: DETECTION OF AMPC BETA LACTAMASE IN 
ACINETOBACTER ISOLATES BY AMP C DISC TEST (n=175) 
 
AMP C BETA 
LACTAMASE NO OF ISOLATES PERCENTAGE % 
Positive 23 13.14% 
Negative 152 86.86 % 
 
 
 175 isolates of Acinetobacter species were screened for Amp C 
beta lactamases by Disc antagonism test. 23(13.14%) isolates were found 
to be Amp C screening test positive and confirmed with Amp C disc test. 
  
32%
2.29%
0.57%
65.14%
A.baumannii
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A.junii
Non ESBL Producers
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TABLE 22: DISTRIBUTION OF AMPC AMONG ACINETOBACTER SPP. 
   (n=175) 
 
 
SPECIES SPECIMEN NUMBER TOTAL PERCENTAGE%
A.baumannii 
 
ET aspirate 8 
21 12% 
Urine 7 
Blood 3 
Wound swab 3 
A.lwoffii 
Blood 1 
2 1.14% 
Urine 1 
 
 
 The AmpC beta lactamase were common in A.baumannii (12%) 
and A.lwoffii (1.14%). 
 
FIGURE14: DISTRIBUTION OF AMP C IN ACINETOBACTER ISOLATES 
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TABLE 23: CLINICAL OUTCOME OF THE PATIENTS WITH 
MEROPENEM RESISTANCE AND THEIR GENETIC MARKAERS 
 
ISOL
ATE 
NO. 
AGE
/SEX 
CLINICAL 
DIAGNOSIS MIC 
GENES TESTED 
CLINICAL 
OUTCOME 
OXA-23 VIM1 IMP1 
1 45/F Urosepsis 256 µg/ml P P N RECOVERED
2 
 47/M Poisoning 
256 
µg/ml P N P RECOVERED
3 43/M RTA/Head injury 
64 
µg/ml P N N EXPIRED 
4 45/M BB Fracture (left) 
64 
µg/ml P N N RECOVERED
5 50/M Post TB 32 µg/ml P N P EXPIRED 
6 34/M Post Renal transplant 
64 
µg/ml P N N RECOVERED
7 48/M Post Renal transplant 
256 
µg/ml P P N RECOVERED
8 35/M Above knee amputation 
128 
µg/ml P N N RECOVERED
9 
 58/M Septicemia 
256 
µg/ml P N N EXPIRED 
10 60/F Poisoning 128 µg/ml P P P EXPIRED 
11 62/F MCTD 128 µg/ml P N P EXPIRED 
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ISOL
ATE 
NO. 
AGE
/SEX 
CLINICAL 
DIAGNOSIS MIC 
GENES TESTED 
CLINICAL 
OUTCOME 
OXA-23 VIM1 IMP1 
12 58/F Pneumonia 64 µg/ml P N P RECOVERED
13 45/M Pneumonia 64 µg/ml P P N RECOVERED
14 58/M Aspiration pneumonitis 
128 
µg/ml P P N RECOVERED
15 40/F Poisoning 128 µg/ml P P N RECOVERED
16 28/M RTA/Head injury 
256 
µg/ml P N P RECOVERED
17 47/M RTA/Head injury/SDH 
256 
µg/ml P P P RECOVERED
18 20/M RTA/Head injury 
256 
µg/ml P P N RECOVERED
19 20/M CSOM 256 µg/ml P P N RECOVERED
20 20/F Post Renal transplant 
256 
µg/ml P N N RECOVERED
        P- Positive, N- Negative 
        Among the 20 patients with meropenem resistant isolates, 5 patients 
expired when compared to 100% recovery in the meropenem susceptible 
group (155 patients).  
 DIRECT GRAM STAIN SHOWING  GRAM NEGATIVE COCCO BACILLI 
 
 
GRAM NEGATIVE COCCO BACILLI  IN CULTURE SMEAR 
 
 
 
 
 
BIOCHEMICAL REACTIONS OF ACINETOBACTER BAUMANNII 
 
 
BIOCHEMICAL REACTIONS OF ACINETOBACTER CALCOACETICUS 
 
 
 
 BIOCHEMICAL REACTIONS OF ACINETOBACTER LWOFFII 
 
 
BIOCHEMICAL REACTIONS OF ACINETOBACTER JUNII 
 
 
 
 MEROPENEM MIC- MACROBROTH DILUTION METHOD 
 
 
MODIFIED HODGE TEST FOR OXACILLINASE DETECTION 
 
 
Meropenem resistant Isolate 2 – MHT Positive,  Isolate 1 - Negative 
 
AMPC DISC TEST FOR AMPC BETA LACTAMASE DETECTION 
 
 
 
Isolate 1&2 - Positive,  3 – Negative 
 
 
IMIPENEM-EDTA COMBINED DISC TEST FOR MBL DETECTION 
 
 
 
 
I – Imipenem                     IE – Imipenem EDTA 
 
  
 CLSI PHENOTYPIC CONFIRMATORY METHOD FOR ESBL 
 
 
PCR FOR BLA-IMP1 GENE 
 
 
 
Isolate No. – 10,11,12 - Positive     LD – DNA ladder    NC – Negative control 
  
PCR FOR BLA-VIM1 GENE 
 
 
 
Isolate No.–15, 17, 18, 19 - Positive   LD- DNA ladder  NC–Negative control 
 
 
PCR FOR OXA-23 GENE 
 
 
 
Isolate No. – 1,2,3,4,5,6,7-Positive     LD- DNA ladder 
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DISCUSSION 
 
 Acinetobacter infections presents a global medical challenge 
because it is an important opportunistic GNB in health care institutions. It 
has gained importance because of its ability to survive under a wide range 
of environmental conditions, having numerous intrinsic and acquired 
drug resistance mechanisms and the emergence of multidrug and pandrug 
resistant strains.[75]  The isolation and identification of resistance pattern 
of Acinetobacter infections helps in selection of appropriate antibiotics,  
reducing the morbidity and mortality of the patients and in reducing the 
spread of resistant strains in the community. 
 
 This cross sectional study was conducted in the Institute of 
Microbiology, Madras Medical College, Chennai during the period 
from Sep 2013 to Aug 2014.  
 
 The present study includes 175 clinically significant, consecutive, 
non-duplicate Acinetobacter isolates. 
 
 In the present study, among the 175 Acinetobacter isolates, 
120(68.57%) isolates were from male patients and remaining 55(31.43%) 
isolates were from female patients (Table-1). The male to female ratio 
was 2.18:1which is high when compared to study done by Muktikesh 
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Dash et al. where he reported male to female ratio of 1.08:1.[76] Out of the 
175isolates, 84 isolates(48.0%) were from the patients in the age group of 
41 – 60 years  followed by 48 isolates (27.43%) in 21 – 40 years age 
group, 33 isolates (18.86%) from patients aged more than 60 years  and 
10 isolates (5.71%) in 18-20 years age group (Table-2). 
 
 In the present study, the distribution of Acinetobacter species in 
various clinical specimens was in the following order, urine specimen 45 
(25.71%), endotracheal aspirate 41 (23.43%), wound swab 41 (23.43%), 
blood 17 (9.71%), sputum (6.86%), bronchial wash (4.00%), PD fluid 
(2.86%), CSF (1.71%), pleural fluid (1.14%) and ascitic fluid (1.14%) 
(Table-3). The maximum number of Acinetobacter isolates were from 
respiratory samples 63(36.00%). This is very similar to the study 
conducted by Apoorva Tripathi et al. where 35.78% of isolates were from 
respiratory specimens[78]  where as Muktikesh Dash et al. in his study 
reported that Acinetobacter isolates were common from pus sample 
56.9%.[76]   
 
 In this study, Acinetobacter isolates were predominantly from 
patients in Intensive care units 20.57%, followed by Medicine unit 
17.71%, Neuro surgery 14.86%, Surgery unit 13.7%, Nephrology 12%, 
orthopaedics ward 8.6%, thoracic medicine 8% and from other wards 
4.57% (Table-4). This is similar to the study conducted by Muktikesh 
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Dash et al. where 45.2% of the isolates were from patients admitted in 
Intensive care units, 26.3% and 19% from patients admitted in surgery 
and medical wards respectively.[76] Similarly Apoorva Tripathi et al. and 
Namita jaggi et al. in their studies documented 61.2% and 76.7% of the 
Acinetobacter isolates were from Intensive care units respectively.[77],[78] 
This implies that Acinetobacter infections are more common in critically 
ill patients in Intensive care units. 
 
 In the present study, four Acinetobacter species were isolated, of 
which A.baumannii 142 (81.14%) was the most common species 
followed by A.lwoffii 18(10.29%), A.calcoaceticus 8 (4.57%) and A.junii 
7(4%) (Table-5). This is similar to the study conducted by Muktikesh 
Dash et al. where he documented that 79.6% isolates were A.baumannii, 
12.4% were A.lwoffii and 8% were other species.[76] Similarly Apoorva 
Tripathi et al. have reported that 74.50% isolates were A.baumannii and 
24.50% were A.lwoffii.[78] Like many other studies, the species most 
commonly isolated in this study was A.baumannii  because of its natural 
habitat in the environment when compared to other species. 
 
 With regard to the species distribution of Acinetobacter isolates in 
various clinical infections in this study, A.baumannii was isolated from 
respiratory tract infections, wound infections, urinary tract infections and 
septicemia. A.lwoffii was isolated from wound infections and UTI. 
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A.calcoaceticus was isolated from wound infections. A.junii was isolated 
from wound infections and septicemia (Table-6). This implies that 
Acinetobacter infections commonly affects the patients with breaches in 
airway and skin integrity.[94] 
 
 The antimicrobial sensitivity pattern of Acinetobacter spp.was 
studied. It differs among the different species. In the present study 
A.baumannii has higher percentage of resistance to various classes of 
antibiotics and the percentage of resistance was as follows, cefotaxime 
(86.62%), ciprofloxacin (80.99%), cotrimoxazole (80.99%), ceftazidime 
(79.58%), gentamicin (73.24%), cefepime (66.91%) and amikacin 
(57.04%), piperacillin tazobactum (38.02%), Imipenem (11.97%), 
Meropenem (14.08%), Tigecycline (16.90%) and polymyxin B (3.52%). 
All the A.baumannii isolates (100%) in this study were sensitive to 
colistin (Table-8). The low resistance pattern of A.baumannii to 
imipenem and meropenem indicate that they can be used as effective 
drugs in the treatment of MDR Acinetobacter infections.[103] 
 
 The sensitivity pattern of A.baumannii was similar to the studies 
done by Neelam taneja et al., Prasanth et al. and Gomty mahajan et al. in 
which the authors have documented more than 70% resistance to 
cephalosporins, aminoglycosides and quinolones.[49],[51],[59] Similarly 
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Sohaila Mushtaq et al. have reported more than 60% resistance to 
cephalosporins and 50% resistance to aminoglycosides and quinolones.[79] 
 
 Imipenem (11.97%)  and Meropenem (14.08%) resistance in 
A.baumannii was low when compared to other studies done by Manu 
chaudhary and Anurag payasi where they have reported 35% resistance 
towards carbapenem drugs.[12] Gladstone et al. Lee et al., Sinha et al., 
Purti tripathi et al. and Apoorva Tripathi et al. have reported 14.2%, 
21.18%, 35%, 43% and 52.63% of imipenem resistance  
respectively.[17],[74],[78],[80] Similarly very high percentage resistance of  
imipenem (89.6%) and meropenem (99%)  was reported by Namita jaggi 
et al. and John et al. respectively.[77],[84]  The very high resistance may be 
due to the ability of the organism to produce more than one hydrolyzing 
enzyme or showing modifications in more than one outer membrane 
porin channels or may be due to selection pressure.[98] 
 
 In the present study, Tigecycline resistance in A.baumannii isolates 
was 16.90%. However tigecycline resistance varies between 8.3% to 
74.8% as documented by Gomty Mahajan et al. and Namita jaggi et al. 
respectively.[51],[59],[77]  The wide variation among the reported studies 
with regard to tigecycline resistance may be due to varying degree of 
mutations in efflux pumps.[104] 
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 Polymyxin B resistance in A.baumannii isolates was (3.52%) and 
all the A.baumannii isolates (100%) were sensitive to colistin. Namita 
jaggi et al. have documented 1.9% resistance to polymyxin-B and 1.2% 
resistance to colistin.[77] This shows that A.baumannii isolates that were 
included in this study have not developed resistance mechanisms like 
efflux pumps or modification of cell membrane lipopolysaccharides for 
the above mentioned drugs.[37],[38]    
 
 The percentage of resistance for A.lwoffii isolates in this study 
was, cotrimoxazole (83.33%), ciprofloxacin (72.22%), cefotaxime 
(66.67%), gentamicin (55.56%), ceftazidime (44.44%), amikacin 
(38.89%), cefepime (27.78%), piperacillin tazobactum (16.67%) and 
tigecycline (5.55%). All the A.lwoffii isolates (100%) were sensitive to 
imipenem, meropenem, polymyxin B and colistin (Table-9). This 
antimicrobial susceptibility pattern is similar to the study done by 
Apoorva Tripathi et al. [78] 
 
 The percentage of resistance for A.calcoaceticus isolates in this 
study was, ciprofloxacin (62.50%),  cotrimoxazole (62.50%),  cefotaxime 
(25%), gentamicin (25%), amikacin (12.50%) and tigecycline (12.50%). 
All the eight isolates (100%) were sensitive to ceftazidime, cefepime, 
piperacillin tazobactum, imipenem, meropenem, polymyxin B and 
colistin (Table-10). 
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 The percentage of resistance for A.junii isolates in this study was 
ciprofloxacin (85.71%), cotrimoxazole (85.71%), gentamicin (85.71%),  
amikacin (57.14%) and cefotaxime (42.86%),  ceftazidime (28.57%), 
cefepime (28.57%), piperacillin tazobactum (14.29%) and tigecycline 
(14.29%). All the seven isolates (100%) were sensitive to imipenem, 
meropenem, polymyxin B and colistin (Table-11). 
 
 In the present study, A.baumannii had higher percentage of 
resistance to third and fourth generation cephalosporins, aminoglycosides 
and quinolones when compared to  A.lwoffii, A.calcoaceticus and A.junii  
which exhibited lesser resistance to cephalosporins, aminoglycosides and 
quinolones.  Whereas A.baumannii exhibited relatively lesser percentage 
of resistance to carbapenems when compared to other species which 
exhibited no resistance or 100% susceptibility to carbapenems. This is 
because of multiple virulence factors of A.baumannii like biofilm 
formation, production of capsule and efflux pumps. Hence there was a 
significant difference (p value <0.05) between the antimicrobial 
sensitivity pattern of A.baumannii and other species (Table-12). 
 
 Multidrug resistance among Acinetobacter spp. is common 
because of its potential to respond quickly to the changes in selective 
environmental pressure and inherent property of having chromosomally 
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encoded AmpC cephalosporinases (ADCs).[94] In the present study Multi 
drug resistance was 60%. This is similar to the study done by Muktikesh 
Dash et al. where he documented 54.7% of MDR.[76] However Gomty 
Mahajan et al. and Purti Tripathi et al. has reported multidrug resistance 
of 70% and 89.71%  respectively.[59],[80] MDR was more common in 
A.baumannii (92.38%) when compared to other species in this study. This 
is similar to the study conducted by Seifert et al. and Prashanth et 
al.[81],[82]  
 
 Extended drug resistance was found to be 11.43% and there were 
no pan drug resistant isolate in this study. Gaynes et al. have documented 
17% of XDR and Jyoti Sharma et al. have documented 22.38% of PDR 
Acinetobacter spp.[95],[96] 
 
 Acinetobacter species are very notorious for their ability to acquire 
antibiotic resistance by beta lactamase production, reduced access to 
bacterial targets and mutations that change targets or cellular functions.[18] 
All the 175 isolates included in this study were screened for production of 
beta lactamases like carbapenamase, extended spectrum beta lactamase 
and Amp C beta lactamase. 
 
 Among the 175 isolates, 20 isolates (11.43%) were found to be 
resistant to meropenem by Kirby Bauer disc diffusion method and all 
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these 20 Acinetobacter isolates belong to baumannii species (Table-13). 
The meropenem resistance in this study was low when compared to the 
study done by Gladstone et al. and Sinha et al. where they have 
documented 14.2%  and 28% of meropenem resistance respectively.[5],[17] 
Very high level of meropenem resistance 89.6% was reported by Namita 
jaggi et al.[77] 
 
 In the present study, among the 20 meropenem resistant isolates, 
17 isolates were resistant to imipenem and the remaining 3 isolates were 
sensitive to imipenem. This is because of the difference in the 
pharmacodynamic property among the carbapenem drugs.[97] This is 
similar to the study done by Muktikesh Dash et al. where 19% resistance 
to imipenem and 22% resistance to meropenem was documented.[76] 
 
 The meropenem resistant isolates by Kirby Bauer disc diffusion 
method were further confirmed for their meropenem resistance by MIC. 
All the 20 isolates have their MIC in the resistant range (≥8 µg/ml), hence 
disc diffusion method correlates with MIC.[48] This shows that the regular 
screening for meropenem resistance can be done using disc diffusion 
method and further confirmed by MIC. 
  
 Among the 20 isolates, 9(45%) isolates have meropenem MIC of 
256µg/ml, 5(25%) isolates have 128 µg/ml, another 5(25%) isolates have 
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64 µg/ml and remaining 1(5%) isolate has 32 µg/ml as MIC (Table-15). 
Amudhan et al. has documented MIC values ranging from 8µg/ml to 
128µg/ml.[83] Maryam Noori et al. have reported meropenem MIC as high 
as 256µg/ml in Iran.[99] In this study 9 isolates have 256µg/ml as MIC, 
indicating the prevalence of  high level resistant strains among the 
isolates.  
 
 The 20 meropenem resistant isolates tested by the indicator method 
(i.e) meropenem disc diffusion were proceeded for the detection of 
carbapenamase production.[5] The mechanism of carbapenam resistance 
by beta lactamases were tested by the following  phenotypic methods – 
Modified Hodge test for oxacillinase, Imipenem-EDTA combined disc 
test for metallo beta lactamase and AmpC disc test for AmpC beta 
lactamase (Table-16). 
 
 Among the 20 meropenem resistant isolates, Modified Hodge test 
was positive in 9/20 (45%) isolates. This was similar to the study done by 
Gomty mahajan et al. (47.6%)[59]. But MHT positivity varies between 
2.2% to 71% in other studies. This may be due to lack of standardization 
of phenotypic procedures for detection of carbapenemase in NFGNBs, as 
there are no standard procedures described in CLSI and other similar 
guidelines. 
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 Imipenem-EDTA combined disc test was positive in 9/20(45%) 
isolates. Sinha et al. and Uma et al. have documented 60.71% and 71% of 
MBL respectively.[20],[23] Similarly Gupta et al., Lee et al. and Franklin et 
al. have documented 7.5%, 14% and 16% MBL respectively.[85],[86],[87] 
The reason for the variations in MBL detection may be due to lack of  
standard procedures and variations in the expression of MBL gene.[98]   
 
 AmpC Disc test was positive in 6/20(30%) isolates which was low 
when compared to Sinha et al. and Deepa et al. where they reported 
60.71% and 73% of AmpC beta lactamases in carbapenem resistant 
isolates respectively.[11],[54] AmpC beta lactamases alone may not be the 
cause for carbapenem resistance but when it is present along with 
decreased membrane permeability, it is capable of conferring carbapenem 
resistance.[5]  
 
 Among the 20 meropenem resistant isolates, 7/20(35%) isolates 
were negative for all the three phenotypic methods. This shows that 
carbapenem resistance in those isolates may be due to non-expression of  
carbapenem resistant genes, altered porin channels and/or efflux pump 
mechanisms. 3/20 (15%) isolates were positive for all the three tests and 
7/20 (35%) isolates were positive for both oxacillinase and metallo beta 
lactamase. This implies that combination of several mechanisms may 
exist in the same isolate to confer carbapenem resistance.[18] 
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 In this study, the 20 isolates which were resistant to Meropenem by 
Disc diffusion method  were subjected to PCR for the detection of the 
most common Oxacillinase gene OXA-23 and Metallo Beta Lactamases 
genes bla-IMP1 and bla-VIM1.[72],[73] 
 
          All the 20 meropenem resistant isolates (100%) were OXA-23 
positive. This is similar to the study done by Yang soon Lee et al. in 
Korea, in the year 2011, where all carbapenem non susceptible isolates 
collected from 9 hospitals were OXA-23 positive (100%).[90] Similarly in 
Iran, Nasrollah Sohrabi et al. have documented 88.7% of OXA-23 
positive isolates.[91] Amongst the Indian studies, the maximum  OXA-23 
positive isolates was reported as 81.89% in the study done by Amudhan 
et al.[83]  Oxacillinases would also inactivate carbapenems, though they 
are less efficient hydrolyzers of carbapenems invitro than MBLs.[59] 
Hence the occurrence of OXA-23 positive isolates also poses therapeutic 
failure . 
 
 Bla-IMP1 was positive in 7 isolates (35%) of the 20 meropenem 
resistant isolates. This is marginally high when compared to the study 
done by Sinha et al. and Lee et al. where they have reported 32.14% and 
28.9% of MBL respectively.[5],[86]  
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 Bla-VIM1 was positive in 9 isolates (45%) (Table-17). This is low 
when compared to the studies done by Manu chaudhary and Lee et al. 
where they have documented 59% and 71.1% of VIM1 respectively.  
 
 All the three genes were positive in 2 (10%) isolates and both 
blaVIM1 and blaIMP1 were positive in 2 (10%) isolates. Amudhan et al. 
have documented 0.86% of all three genes positive isolates.[83] Similarly 
Sinha et al. have documented 7.14% of both VIM1 and IMP1 positive 
isolates.[5] 
 
 In this study, OXA-23 was positive in all the 20 meropenem 
resistant isolates. Amongst the 20 meropenem resistant isolates MHT was 
positive only in 9 isolates. Similarly amongst 14 MBL genes (blaVIM1 & 
IMP1) positive isolates, only 9 isolates tested positive in Imipenem-
EDTA combined disc test. Hence the detection of various 
carbapenemases by genotypic method was more sensitive when compared 
to phenotypic methods.[105]   
 
 The occurrence of MBL has tremendous therapeutic consequences 
because they also carry other multidrug resistance genes. Although MBLs 
are less in Acinetobacters than OXA type carbapenamases, they have 
100-1000 fold high hydrolytic activities towards carbapenems and also 
they have the ability to participate in horizontal gene transfer among 
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other GNBs.[59] Hence the identification of MBL and oxacillinase 
producing isolate is also essential for the infection control management. 
  
 Extended spectrum beta lactamases continues to be a major 
challenge in health care institutions, hence the knowledge about their 
prevalence is an essential guide towards appropriate antibiotic treatment. 
In the present study all the 175 isolates were screened for ESBL 
production. 61(34.86%) isolates were found to be ESBL producers. The 
Extended spectrum beta lactamases were common in A.baumannii 
(91.80%), followed by A.lwoffii (6.56%) and A.junii (1.64%). Sinha et al. 
have reported 28% of ESBL in Acinetobacter spp. and 69.04% of it was 
due to A.baumannii and 30.96% was due to A.lwoffii.[74] Vahaboglu et al, 
Yong et al. and Manu chaudhary et al. have documented ESBL 
production of 46%, 54.63% and 83.6% respectively.[12],[88][89] None of the 
meropenem resistant isolates were ESBL producers. 
  
 The 175 isolates in the present study were screened for AmpC 
beta lactamases. 23(13.14%) isolates were found to be AmpC producers. 
AmpC beta lactamases were also common in A.baumannii (91.30%) 
followed by A.lwoffii (8.70%). This was low when compared to the study 
done by Singhal et al where she reported 28.57% of AmpC beta 
lactamases in Acinetobacter spp.[60] 
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 The treatment of Acinetobacter infections remains a great 
challenge because resistance to aminoglycosides, cephalosporins and 
quinolones has substantially increased worldwide. Carbapenems are the 
drug of choice for MDR Acinetobacter infections, for ESBL and AmpC 
producing isolates, but resistance to carbapenems by the production of 
carbapenamases and various other mechanisms has limited the 
therapeutic options. The recently approved tigecycline for multi drug 
resistant isolates have limited clinical applications because of its 
toxicities and its unavailability in most of the countries. Because of 
increasing carbapenem resistance and limited therapeutic options 
available, the old antibiotic colistin is being used more extensively 
nowadays, but resistance to colistin has also been reported. But in my 
study no resistance was detected for colistin among the isolates.[51],[77],[92] 
Hence currently combination therapy like meropenem with tigecycline 
and colistin with sulbactum or rifampicin are being  tried in the treatment 
of Acinetobacter infections.[38],[44],[46] 
 
 The clinical outcome of the patients with meropenem resistance 
was determined in this study. Among the 20 patients with meropenem 
resistant isolates, 5 patients expired when compared to 100% recovery in 
the meropenem susceptible group (155 patients). OXA-23 was positive in 
all the five patients, blaIMP1 was positive in 3 patients and blaVIM1 was 
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positive in a single patient. All the three genes were positive in one 
patient. The mortality rate in patients with MBL gene was 21.43%, this is 
low when compared to the mortality rate of 44.44% as documented by 
Sinha et al.[20]   
 
 Hence the prevalence of Acinetobacter infections emphasizes the 
need for early detection of various beta lactamases, which would help in 
selection of appropriate antibiotic regimen and prevention of emergence 
and dissemination of MDR strains.   
 
  
  
 
 
 
Summary 
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SUMMARY 
 
 Clinically significant, consecutive, non duplicate Acinetobacter 
isolates (n=175) from various clinical specimens were included in 
this study. 
 There was a male predominance among the cases (68.57%). 
 Maximum number of cases occurred in the age group of 41 – 60 
years (48%). 
 Majority of the isolates were from urine (25.71%), followed by 
endotracheal aspirate (23.43%) and wound swab (23.43%). Blood 
accounts for 9.71% of the isolates. Remaining isolates were from 
sputum (6.86%), bronchial wash (4.00%), PD fluid (2.86%), CSF 
(1.71%), pleural fluid (1.14%) and ascitic fluid (1.14%). 
 Acinetobacter isolates were predominantly from patients in 
Intensive care units 20.57%, followed by Medicine unit 17.71%, 
Neuro surgery 14.86%, Surgery unit 13.7%, Nephrology 12%, 
orthopaedics ward 8.6%, thoracic medicine 8% and from other 
wards 4.57%. 
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 Acinetobacter baumannii (81.14%) was the most common species 
isolated followed by A.lwoffii (10.29%), A.calcoaceticus (4.57%) 
and A.junii (4%). 
 A.baumannii was isolated from respiratory tract infections, wound 
infections, urinary tract infections and septicemia. A.lwoffii was 
isolated from wound infections and UTI. A.calcoaceticus was 
isolated from wound infections. A.junii was isolated from wound 
infections and septicemia.  
 In the present study, A.baumannii had higher percentage of 
resistance to third and fourth generation cephalosporins, 
aminoglycosides and quinolones when compared to A.lwoffii, 
A.calcoaceticus and A.junii which exhibited lesser resistance to 
cephalosporins, aminoglycosides and quinolones. Whereas 
A.baumannii exhibited relatively lesser percentage of resistance to 
carbapenems when compared to other species which exhibited no 
resistance (0%) or 100% susceptibility to carbapenems. Hence 
there was a significant difference (p value <0.05) between the 
antimicrobial sensitivity pattern of A.baumannii and other species.  
 Multidrug resistant in Acinetobacter spp. was found to be 60%. 
Higher percentage of MDR was found in A.baumannii (92.38%) 
when compared to other species. 
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 Extended drug resistance was found to be 11.43% and there was 
no pan drug resistant isolate in this study. 
 20 isolates (11.43%) were found to be resistant to meropenem by 
Kirby Bauer disc diffusion method and all these 20 isolates were 
A.baumannii. 
 All the 20 isolates have their MIC above 8 µg/ml, hence disc 
diffusion method correlates with MIC. 
 Among the 20 isolates, Modified Hodge test was positive in 9 
(45%) isolates, IEDT was positive in 9(45%) isolates, AmpC Disc 
test was positive in 6(30%) isolates and 7(35%) isolates were 
negative for all the three phenotypic methods. Of the 20 isolates, 3 
isolates were positive for MHT, IEDT and AmpC disc test and 7 
isolates were positive for MHT and IEDT. 
 Among the 20 meropenem resistant isolates, all the 20 isolates 
were positive for OXA-23 (100%), 9 (30%) isolates were positive 
for blaVIM1 and 7 (35%) isolates were positive for blaIMP1. 
 61(34.86%) isolates were found to be ESBL producers and 
A.baumannii was the predominant species (91.80%). 
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 23(13.14%) isolates were found to be AmpC beta lactamase 
producers and A.baumannii was the predominant species (91.30%).  
 The clinical outcome of the patients with meropenem resistance 
was determined in this study. Among the 20 patients with 
meropenem resistant isolates, 5 patients expired when compared to 
100% recovery in the meropenem susceptible group. 
 The mortality rate in patients with MBL gene was 21.43%. 
 
  
 
 
 
 
 
 
Conclusion 
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CONCLUSION 
 
 Acinetobacter species are the second most common nonfermenter 
isolated from clinical specimens next to Pseudomonas species. The 
infections caused by MDR Acinetobacter that are capable of producing 
various beta lactamases are associated with significant morbidity and 
mortality. Hence Acinetobacter has been added to the list of significant 
microbial challenges of current era.  
 
 Although A.baumannii was the most common species isolated from 
patients with various clinical diseases, other species like A.lwoffii, 
A.calcoaceticus and A.junii were also isolated in a proportion of clinical 
infections. A.baumannii was the most resistant when compared to other 
Acinetobacter species and there was a significant difference in their 
antimicrobial sensitivity pattern.  
 
 MDR Acinetobacter infections were predominant and XDR 
Acinetobacter infections have also been recorded but no PDR 
Acinetobacter was isolated in this study. Extended spectrum beta 
lactamases and AmpC beta lactamases were also detected in a significant 
number of Acinetobacter isolates, implifying their contribution to 
multidrug resistance.       
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          Carbapenems remain the drug of choice for the MDR acinetobacter 
infections. But resistance to carbapenems due to production of various 
beta lactamases is of great concern as they are encoded by genes which 
are horizontally transmissible. There is difference between phenotypic 
and genotypic methods in the sensitivity of detection of carbapenamases 
where genotypic methods are more sensitive and remain the gold 
standard. 
 
 In this study, gene coding for oxacillinase was positive in 100% 
and MBL genes in 70% of meropenem resistant isolates. Among the 
MBL genes, blaVIM1 (45%) was more common than blaIMP1 (35%). 
Oxacillinases also confer resistance to carbapenems, although they are 
less efficient hydrolyzers of carbapenems when compared to MBLs. The 
occurrence of MBL is not only a therapeutic issue, but poses a serious 
concern for infection control as well. Hence the treatment option is left 
with the polymyxin-B and colistin which are highly nephrotoxic and 
neurotoxic. In this study 3.52% of isolates were resistant to polymyxin-B 
and all the isolates (100%) were susceptible to colistin. 
 
 The high prevalence of Acinetobacter infections emphasizes the 
need for early detection of various beta lactamases, which would help in 
selection of appropriate antibiotic regimen and prevention of emergence 
and dissemination of MDR strains. Hence, methods for detection of 
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carbapenamases have to be standardized by formulating guidelines and be 
routinely used. 
 
 The present need is that all the health care institutions should have 
a coordinated effort to curtail inappropriate use of antibiotics, their own 
antimicrobial stewardship program, vigilant detection of resistant 
Acinetobacters, regular surveillance and infection control protocols to 
control the increasing incidence of highly resistant Acinetobacters.  
 
 
 
 
 
 
Appendix 
  
APPENDIX-I 
ABBREVIATIONS 
GNB   -  Gram Negative Bacilli 
NFGNF  -  Non fermentative Gram negative bacilli 
A.calcoaceticus -  Acinetobacter calcoaceticus 
A.baumannii  -  Acinetobacter baumannii 
A.haemolyticus -  Acinetobacter haemolyticus 
A.lwoffii                   -  Acinetobacter lwoffii 
A.junii                      -  Acinetobacter junii 
A.johnsonii              -  Acinetobacter johnsonii 
PD fluid                    -  Peritoneal Dialysate fluid 
CSF                           -  Cerebro spinal fluid 
ET aspirate                -  Enditracheal aspirate 
Br Wash                    - Bronchial Wash          
CLED                        - Cysteine Lactose Electrolyte Defecient Medium 
MH broth                  - Mueller Hinton broth 
MHA                         - Mueller Hinton Agar 
ATCC                        - American Type Culture Collection 
CLSI                          - Clinical & Laboratory Standards Institute 
MIC                           - Minimum Inhibitory Concentration 
PCR                           - Polymerase chain reaction 
bp                           - base pair 
ESBL                         - Extended spectrum beta lactamase 
MBL                          - Metallo beta lactamase 
IEDT                          -  mipenem-EDTA combined disc test 
MHT                          - Modified Hodge Test  
EDTA                        -  thylene Diamine Tetra acetic Acid 
OF                              - Oxidation Fermentation 
OXA-23                     - Oxacillinase beta lactamase 
bla-IMP                      - Imipenamase metallo beta lactamase 
 bla-VIM                    - Verona integron encoded metallo beta lactamase 
ICU                            - Intensive care unit 
NS                              - Neuro Surgery 
MED                          - Medicine 
SUR                           - Surgery  
UTI                            - Urinary tract infection 
SEN                           - Sensitive 
RES                           - Resistant 
 
 
  
APPENDIX - II 
A. STAINS AND REAGENTS 
Gram staining: 
Methyl violet (2%)   l0g Methyl violet in 100ml Absolute  
     alcohol in 1 litre of Distilled water  
     (primary stain) 
 
 Grams Iodine    l0g Iodine in 20g KI (fixative) 
 
 Acetone    Decolorizing agent 
 
 Carbol fuchsin (1%)   Secondary stain 
 
 
B. MEDIA USED 
 
1. Mac Conkey agar: 
                         
Peptone     20 g 
Sodium taurocholate    5 g 
Distilled Water    1 ltr 
Agar      20 g 
2% neutral red in 50% ethanol  3.5 ml 
10% lactose solution    l00 ml 
 
 Dissolve peptone and taurocholate in water by heating. Add agar and dissolve it 
in steamer. Adjust pH to 7.5. Add lactose and neutral red shake well and mix. Heat in 
free steam (100°C) for 1 hour then autoclave at 115°C for 15 minutes. 
 
2. Blood agar (5% sheep blood agar): 
 
Peptone     l0g 
NaCl      5g 
Distilled water     1 Ltr 
Agar      l0g 
 
 Dissolve ingredients in distilled water by boiling, and add 5% sheep blood 
(sterile) at 55°C adjust pH to 7.4. 
 
3. Mueller- Hinton Agar: 
 
Ingredients                                          Gms / Litre 
Beef infusion     300ml 
Caesein hydrolysate    17.5g 
Starch      1.5g 
Agar      l0g 
Distilled water     l Ltr 
pH = 7.4 
 
 22 grams of media is suspended in 1000 ml of distilled water. Dissolve the 
medium completely. Dispense and sterilize by autoclaving at 115-121°C for 10 minutes. 
DO NOT OVERHEAT. 
MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION:  
 
1. Catalase Test: 
 
              3% hydrogen peroxide. 
 
2.Oxidase Reagent: 
 
 Tetra methyl p-phenylene diamine dihyrochloride- 1%aqueous solution. 
 
3.Indole test: 
 
Kovac’s reagent 
 
Amyl or isoamyl alcohol                           150ml 
Para dimethyl amino benzaldehyde           10g 
Concentrated hydrochloric acid                 50ml 
 
 Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in small 
quantities and store in the refrigerator. Shake gently before use. 
 
4. Simmon’s Citrate Medium: 
 
 Koser’s medium    1 ltr 
 Agar                                           20g 
 Bromothymol blue 0.2%            40ml 
 
 Dispense, autoclave at 121°C for 15 min and allow to set as slopes. 
5.Triple Sugar Iron medium: 
 
Beef extract                                3g 
Yeast extract                              3g 
Peptone                                      20g 
Glucose                                      1g 
Lactose                                       10g 
Sucrose                                       10g 
Ferric citrate                               0.3g 
Sodium chloride                         5g 
Sodum thiosulphate                    0.3g 
Agar                                            12g 
Phenol red 0.2% solution            12ml 
Distilled water                             1 Lt 
 
 Heat to dissolve the solids, add the indicator solution, mix and tube. Sterilize at 
121°C for 15 min and cool to form slopes with deep butts. 
 
9. Mannitol motility medium 
 
Agar                                                5g 
Peptone                                           1g 
Potassium nitrate                             1g 
Mannitol                                          2g 
Phenol red indicator 
Distilled water                                   l000ml 
 pH 7.2 
 
 
8.Decarboxylase media: 
 
8a.Moller decarboxylase broth base: 
 
 Ingredients                                  gms/L 
 Peptone                                           5 
 Beef extract                                     5 
 Bromocresol purple                       0.01 
Cresol red                                      0.005 
Glucose                                          0.5 
Pyridoxal                                        0.005 
Final pH 6 
8b. Aminoacid: 
 
 Add 10 g of the levo form of the aminoacid for 1000ml.mix and dispense in 
sterile tubes. 
 
9. Hugh & Leifson’s Oxidation –Fermentation test: 
 
Peptone                                   2g 
Sodium chloride                     5g 
D-glucose                              10g 
Bromothymol blue                 0.03g 
Agar                                       3.0g 
Dipotassium phosphate         0.30g 
Distilled water                        1Lt 
pH =7.1 
            Basal medium is autoclaved.1% of sterile sugar solutions is added to the basal 
medium. Dispense into sterile test tubes without slant. 
10. Malonate Utilization test: 
 
Yeast Extract                            1 g 
Ammonium sulphate                2 g 
Dipotassium phosphate            0.6 g 
Potassium phosphate                0.4 g 
Sodium chloride                       2 g 
Sodium malonate                     3 g 
Bromothymol blue                   0.025g 
Distilled water                          1 Lt 
Adjust the pH to 7.4. Sterilize by autoclaving at 121C for 15min. 
 
11. EDTA solution: 
 
       0.5M EDTA solution was prepared by adding 186.1gm of disodium EDTA in 
1000ml of distilled water. pH was 8. Sterilized by autoclaving at 121°C for 15 min. 
 
 
 
 
 
 
 
Annexure 
                     ANNEXURE-I  -  CERTIFICATE OF APPROVAL 
  
ANNEXURE-II - PROFORMA 
 
 Isolate  No  : 
 Name           :                                                                   IP no  : 
 Age              :                                                                    Ward   : 
 Sex               :                                                                    D.O.A : 
 Address        :                                                                   D.O.D : 
 
 Source of the 
          Specimen            : 
Invasive procedures     : 
(catheterization,IV line,Mechanical intubation). 
 
           Clinical Diagnosis        : 
 
           Treatment  History       : 
 
Microbiological investigation: 
1. Confirmation of the Isolate       : 
 
2. Speciation                                  : 
 
Growth 
at 
Hemolysis 
on  BAP 
OF 
dextrose 
test 
Arginine Malonate 
utilisation
Gelatin 
liquefaction 
Chloramphenicol
Sensitivity 
37 
ºC 
42 
ºC 
        
 
 
3. Name of the species identified    : 
 
4. Antimicrobial sensitivity pattern: 
                                   Sensitive to     : 
                           Resistance to  :   
5. Resistance pattern identified      : 
 
6. MBL gene detection by PCR     : 
 
  
ANNEXURE-III - CONSENT FORM 
 
 
STUDY TITLE : “Speciation of Acinetobacter isolates and Detection of Resistance 
patterns by Phenotypic & Genotypic Method”. 
 
 I…………………………………………, hereby give consent to participate in 
the study conducted by Dr.J.Thiriveni, Post graduate at Institute of Microbiology, 
Madras Medical College, Chennai and to use my personal clinical data and the result of 
investigations for the purpose of study, I also give consent to give my clinical Specimen 
(urine,blood,pus,sputum,CSF,Asciticfluid, Plueral fluid, Tracheal swab and Bronchial 
wash.) for further investigations.I also learn that there is no additional risk in this study. I 
also give my consent for my investigator to publish the data in any forum or journal. 
 
 
Signature/ Thumb impression                                   Place                             Date 
Of the patient/ relative 
Patient Name & Address: 
 
 
Signature of the investigator: 
Signature of the Guide         : 
  
   
ANNEXURE – IV    MASTER CHART 
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